System and method for intracranial endovascular ultrasound delivery
The catheter-based ultrasound system addresses skull-dependent limitations by delivering acoustic energy radially from intracranial vasculature, facilitating precise therapeutic interventions and BBB modulation for enhanced drug delivery to critical brain regions.
Patent Information
- Application Number
- PCT/US2026/026294
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-10-03
- Filing Date
- 2026-05-01
- Publication Date
- 2026-11-12
AI Technical Summary
Existing ultrasound systems for intracranial applications face limitations due to skull attenuation, require transcranial beam steering, and lack radial energy delivery capabilities, hindering precise and adaptable therapeutic and diagnostic interventions in intracranial vasculature.
A catheter-based ultrasound system with integrated transducer elements and a control system that emits acoustic energy radially or circumferentially from within intracranial vasculature, utilizing a low-acoustic-attenuation material and passive cavitation detection for real-time feedback, enabling BBB modulation and therapeutic agent delivery without extracranial beam steering.
Enables precise and adaptable therapeutic interventions, including BBB modulation and targeted drug delivery to critical brain structures, overcoming skull-dependent constraints and enhancing treatment efficacy while minimizing systemic side effects.
Smart Images

Figure US2026026294_12112026_PF_FP_ABST
Abstract
Description
CHZ-00225SYSTEM AND METHOD FOR INTRACRANIAL ENDOVASCULAR ULTRASOUND DELIVERY CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional App. No. 63 / 892,904, filed on October 3, 2025, and U.S. Provisional App. No. 63 / 799,361, filed on May 3, 2025; the entire contents of each application is hereby incorporated by reference.SUMMARY OF THE DISCLOSED SUBJECT MATTER
[0002] The purpose and advantages of the disclosed subject matter will be set forth and apparent from the description that follows, as well as will be learned by practice of the disclosed subject matter. Additional advantages of the disclosed subject matter will be realized and attained by the devices particularly pointed out in the written description and claims hereof, as well as from the appended drawings.
[0003] In a first aspect, the disclosed subject matter provides a catheter-based ultrasound system (catheter system) for therapeutic or diagnostic energy delivery from within intracranial vasculature, comprising an elongated flexible catheter body configured for navigation through intracranial arteries or dural venous sinuses including the superior sagittal sinus, straight sinus, transverse sinus, sigmoid sinus, inferior sagittal sinus, basal vein of Rosenthal, or vein of Galen; at least one ultrasound transducer element integrated within or at the distal portion of said catheter body; an acoustic window formed in the catheter wall or at the catheter tip, composed of a low-acoustic-attenuation material; and a control system operatively connected to said transducer element; wherein said transducer is configured to emit acoustic energy in at least one emission mode selected from: radially outward from the catheter body, circumferentially around the catheter body, focused to a defined tissue depth, or axially forward from the catheter tip; and wherein the system operates without requiring transcranial beam steering or extracranial phased-array control.
[0004] In some implementations, the ultrasound transducer element is frequency-tunable across 1 kHz to 100 MHz, and a frequency of the ultrasound transducer element is adjusted based on target tissue depth and acoustic impedance.
[0005] In some implementations, the acoustic window enables at least 180-degree radial emission.
[0006] In some implementations, the catheter system further comprises at least one drug delivery lumen and at least one cooling lumen, wherein said lumens operate independently from the ultrasound transducer element.CHZ-00225
[0007] In some implementations, the catheter system further comprises a fiberoptic element configured to transmit control signals, receive feedback, or deliver optical energy for adjunctive therapy or sensing.
[0008] In some implementations, the catheter system further comprises an expandable scaffold proximal to the ultrasound transducer element, configured to maintain catheter position, center the ultrasound transducer element within a vessel lumen, and prevent direct vessel wall contact.
[0009] In some implementations, the catheter system further comprises a temperature sensor, wherein the control system is configured as a closed-loop control system comprising a feedback controller configured to adjust energy delivery based on inputs from the temperature sensor to maintain a thermal dose below reversible tissue injury thresholds.
[0010] In some implementations, the catheter system further comprises a passive cavitation detection subsystem comprising at least one passive acoustic detector configured to detect sub-harmonic, ultra-harmonic, and broadband acoustic emissions, wherein the control system adjusts output power based on cavitation spectral signatures.
[0011] In some implementations, the ultrasound transducer element is capable of switching between an imaging mode and a therapeutic mode.
[0012] In some implementations, the catheter body includes a steerable distal segment for navigating tortuous intracranial vasculature.
[0013] In some implementations, the catheter body is configured for deployment within the straight sinus, and the system further comprises a multi-element curved phased array conforming to a triangular cross-section of the straight sinus, the multi-element curved phased array comprising the at least one ultrasound transducer element.
[0014] In some implementations, the catheter system further includes platinumiridium radiopaque markers for fluoroscopic position confirmation.
[0015] In a second aspect, the disclosed subject matter provides a method for bloodbrain barrier modulation comprising: positioning a catheter within a dural venous sinus of a subject; administering a microbubble contrast agent systemically; delivering pulsed focused ultrasound energy through said catheter at a mechanical index between 0.1 and 0.7 and an spatial-peak temporal-average intensity (ISPTA) of 720 mW / cm2 or less; and administering a therapeutic agent systemically within 15 to 120 minutes following delivery of said pulsed focused ultrasound energy; wherein the therapeutic agent achieves enhanced brain tissue concentration relative to administration without prior ultrasound treatment.CHZ-00225
[0016] In some implementations, the therapeutic agent is an anti-amyloid beta antibody selected from lecanemab, donanemab, or aducanumab, and the dural venous sinus is the straight sinus.
[0017] In some implementations, the therapeutic agent is an adeno-associated viral (AAV) vector carrying a therapeutic transgene.
[0018] In some implementations, the therapeutic agent is a lipid nanoparticle construct carrying mRNA, siRNA, antisense oligonucleotide, or CRISPR-Cas9 gene editing components.
[0019] In some implementations, the therapeutic agent is a cell-based therapeutic construct.
[0020] In some implementations, the method further comprises monitoring cavitation signatures via passive cavitation detection elements integrated into the catheter, and adjusting ultrasound output parameters in real time based on said signatures.
[0021] In some implementations, the dural venous sinus is the superior sagittal sinus, and acoustic energy is emitted radially outward to target medial cortical structures including the posterior cingulate cortex and precuneus.
[0022] In a third aspect, the disclosed subject matter provides an intravascular focused ultrasound catheter system configured for deployment within the straight sinus, comprising: an elongated catheter body with an outer diameter of 4.5 mm or less; a multielement curved piezoelectric transducer array configured to conform to the internal geometry of the straight sinus and to electronically steer an acoustic focus to depths of 10 to 60 mm from the sinus lumen; at least two passive cavitation detection elements co-located on the catheter body adjacent to the therapeutic array; a closed-loop control system configured to distinguish stable cavitation from inertial cavitation based on detected acoustic spectra and to adjust output power accordingly; and at least one irrigation lumen for delivery of heparinized saline.
[0023] In some implementations, the transducer array comprises PMN-PT single crystal elements with an electromechanical coupling coefficient kt greater than 0.65.
[0024] In some implementations, the closed-loop control system is configured to: increase output pressure upon absence of stable cavitation signature; reduce output pressure by at least 30% upon detection of inertial cavitation signature; and abort treatment of a sonication zone upon detection of broadband noise elevation exceeding 40 dB above baseline.CHZ-00225
[0025] In a fourth aspect, the disclosed subject matter provides a method for delivering a therapeutic agent to hippocampal or entorhinal cortex tissue in a subject with a neurological condition, comprising: advancing an ultrasound catheter through the venous system to the straight sinus via an access route; delivering pulsed ultrasound energy from said catheter in combination with systemically administered microbubbles to transiently increase blood-brain barrier permeability in tissue anatomically adjacent to the straight sinus; and administering said therapeutic agent systemically within a defined time window following blood-brain barrier opening; wherein said therapeutic agent is selected from the group consisting of an anti-amyloid antibody, an anti-tau antibody, a viral gene therapy vector, a lipid nanoparticle nucleic acid delivery construct, a CRISPR-Cas9 gene editing complex, a small-molecule CNS drug, and a cell-based therapeutic.
[0026] In some implementations, the neurological condition is Alzheimer’s disease, and the therapeutic agent is an anti-amyloid protofibril antibody.
[0027] In some implementations, the therapeutic agent is a gene therapy vector comprising AAV serotype selected from AAV1, AAV2, AAV5, AAV9, or AAVrhlO, carrying a therapeutic transgene for neuronal or glial expression.
[0028] In some implementations, the method further comprises: obtaining preprocedure MR venography; planning sonication zones on treatment planning software; and confirming blood-brain barrier opening by gadolinium-enhanced MRI within 60 minutes of procedure completion.
[0029] In a fifth aspect, the disclosed subject matter provides a catheter-based acoustic energy delivery system for superior sagittal sinus deployment, comprising: a catheter body navigable within the superior sagittal sinus lumen; at least one transducer element oriented to emit acoustic energy radially outward through the sinus wall, dura mater, and cerebrospinal fluid toward ipsilateral cerebral cortex; an acoustic window integrated into the catheter wall; and a control system configurable to operate in at least two of the following modes: blood-brain barrier modulation mode, thermal ablation mode, neuromodulation mode, and intravascular imaging mode.
[0030] In some implementations, in blood-brain barrier modulation mode the system operates at a mechanical index between 0.2 and 0.6 with pulsed waveforms; in thermal ablation mode the system operates at high-intensity continuous or high-duty -cycle waveforms; in neuromodulation mode the system operates at ISPTA below 100 mW / cm2 with pulsed low-duty -cycle waveforms; and in intravascular imaging mode the system operates at frequencies between 20 MHz and 50 MHz in pulse-echo mode.CHZ-00225
[0031] In a sixth aspect, the disclosed subject matter provides a therapeutic and diagnostic ultrasound system for intracranial vessel applications, comprising: an elongated catheter body configured for navigation through intracranial arteries or veins; at least one ultrasound transducer element integrated within or at the distal end of said catheter body; an acoustic window formed in the catheter wall or at the catheter tip, composed of a material selected from the group consisting of Pebax and other low-attenuation acoustic transmission materials; and a control system operatively connected to said transducer element; wherein said transducer is configured to emit acoustic energy in at least one of the following directions: radially outward from the catheter body, circumferentially around the catheter body, or axially forward from the catheter tip; and wherein the system operates without requiring transcranial beam steering or extracranial phased-array control.
[0032] In some implementations, the ultrasound transducer element is tunable across 1 kHz to 100 MHz, and a frequency of the ultrasound transducer element is adjusted based on tissue acoustic impedance.
[0033] In some implementations, the acoustic window enables at least 180-degree radial emission and includes angular emission control.
[0034] In some implementations, the system further comprises at least one drug delivery lumen and at least one cooling lumen, wherein said lumens operate independently from the ultrasound transducer element.
[0035] In some implementations, the system further comprises a fiberoptic element configured to transmit control signals, receive feedback, or deliver optical energy for adjunctive therapy or sensing.
[0036] In some implementations, the system further comprises an expandable scaffold proximal to the ultrasound transducer element, configured to maintain catheter position, center the ultrasound transducer element within a vessel lumen, and prevent direct vessel wall contact.
[0037] In some implementations, the system further comprises a temperature sensor and a proximity sensor, wherein the control system is configured as a closed-loop control system comprising a feedback controller configured to adjust energy delivery based on inputs from the temperature sensor and the proximity sensor.
[0038] In some implementations, the catheter body includes a steerable distal segment for navigating tortuous intracranial vasculature.
[0039] In some implementations, the system further includes positional sensing for real-time emitter localization.CHZ-00225
[0040] In some implementations, the ultrasound transducer element is capable of switching between an imaging mode and a therapeutic mode.
[0041] In some implementations, the control system includes a programmable console configured to adjust emission frequency, pulse duration, and treatment sequence in real time.
[0042] In some implementations, the system is further configured to monitor intravascular structures, comprising: a signal processing unit for detecting and characterizing the presence of indwelling medical devices, thrombi, calcifications, or foreign bodies within the vessel lumen based on acoustic backscatter or Doppler signatures; wherein said monitoring capability is operable in real-time and co-registered with energy delivery pathways.
[0043] In a seventh aspect, the disclosed subject matter provides a method for delivering therapeutic or diagnostic acoustic energy within an intracranial vessel, comprising: positioning a catheter within an intracranial artery or vein; generating acoustic energy at a frequency between 1 kHz and 100 MHz; emitting said acoustic energy through an acoustic window located in the catheter wall or catheter tip in a direction selected from the group consisting of radial, circumferential, and axial emission; and modulating said energy delivery based on proximity to vessel walls or surrounding tissue; wherein said method does not require transcranial beam steering or extracranial phased-array control.
[0044] In some implementations, the method further comprises measuring tissue temperature, adjusting emission parameters based on the temperature, and delivering a therapeutic compound concurrently.
[0045] In some implementations, positioning the catheter includes advancement through a guide catheter, placement under fluoroscopic or ultrasound imaging, and deployment of a scaffold to anchor position.
[0046] In some implementations, modulating energy delivery includes real-time distance monitoring, adaptive energy output based on proximity and tissue compliance, and frequency adjustment based on feedback.
[0047] In some implementations, the method further comprises measuring blood flow velocity or pulsatility, modifying treatment parameters based on flow dynamics, and logging treatment data via fiberoptic telemetry.
[0048] In some implementations, emission is pulsed with a variable duty cycle, and active cooling is applied between pulses.
[0049] In some implementations, the method further comprises administering a sensitizing agent or microbubble contrast during acoustic emission.CHZ-00225
[0050] In an eighth aspect, the disclosed subject matter provides an intravascular focused ultrasound catheter system for ablation of hepatic, pancreatic, renal, adrenal, and retroperitoneal tumors, the system comprising: a flexible elongated catheter body having a proximal connector end and a distal therapeutic end, wherein the catheter is configured for percutaneous deployment within the inferior vena cava or a hepatic vein via femoral venous access; a dual-frequency phased array transducer assembly disposed at the distal therapeutic end, comprising: a first set of piezoelectric elements configured to transmit and receive ultrasound at a first imaging frequency in the range of 5-15 MHz for real-time B-mode visualization of target tissue, and a second set of piezoelectric elements configured to transmit focused ultrasound at a second therapeutic frequency in the range of 1-3 MHz for thermal ablation of said target tissue; an electronic beamforming system operatively coupled to the transducer assembly, configured to electronically steer a therapeutic focal zone to a selectable depth of 10-100 mm from the a longitudinal axis of the catheter body without physical repositioning of the catheter; and a processor executing a closed-loop thermal dosimetry algorithm configured to estimate cumulative thermal dose at the focal zone from acoustic backscatter data and to terminate therapeutic ultrasound delivery upon reaching a predetermined thermal dose threshold.
[0051] In some implementations, the first and second sets of piezoelectric elements are interleaved in a linear array configuration along the longitudinal axis of the catheter body, separated by an acoustic isolation layer, and both sets share a common acoustic lens providing a default geometric focus at 25-35 mm from the longitudinal axis of the catheter body.
[0052] In some implementations, the piezoelectric elements comprise PMN-PT single crystal material having a piezoelectric constant dii of at least 1200 pC / N, enabling high-efficiency acoustic power generation from a catheter outer diameter of 4.0-5.0 mm.
[0053] In some implementations, the system further comprises one or more passive cavitation detection elements disposed on the catheter body within 10 mm of the transducer assembly, configured to detect sub-harmonic and broadband acoustic emissions during therapeutic operation, and a hardware interlock configured to reduce therapeutic power by at least 30% within 2 ms upon detection of inertial cavitation signatures.
[0054] In some implementations, the system further comprises an active cooling lumen configured to deliver a cooling fluid at a flow rate of 20-50 mL / min through the catheter distal segment, and one or more exit ports disposed proximal to the transducerCHZ-00225assembly, wherein said cooling fluid reduces IVC wall temperature to maintain tissue temperature at the vessel wall below 43 °C during therapeutic operation.
[0055] In some implementations, the system further comprises a motion compensation system comprising: a real-time speckle tracking algorithm operating on sequential B-mode image frames at a frame rate of at least 20 Hz to estimate 2D displacement of the target tissue; and a beamforming correction system configured to apply phase delays to the second set of piezoelectric elements to dynamically track the moving focal target within a compensation range of ±5 mm.
[0056] In some implementations, therapeutic ultrasound delivery is gated to respiratory exhalation phases, as determined from acoustic signal variance in the B-mode imaging data, to reduce motion artifacts during ablation of hepatic targets subject to respiratory excursion.
[0057] In some implementations, tissue temperature is estimated by analysis of frequency -dependent backscatter spectral shift in echoes received by the first piezoelectric elements, exploiting the temperature dependence of tissue speed of sound, without requiring external thermometry apparatus.
[0058] In a ninth aspect, the disclosed subject matter provides a method for thermally ablating a tumor (e.g., liver or pancreatic tumor) using an endovascular approach, the method comprising: percutaneously inserting a dual-mode focused ultrasound catheter into a femoral vein and advancing the catheter to a position within the inferior vena cava or a hepatic vein anatomically adjacent to the tumor; activating a high-frequency imaging mode of the catheter at 5-15 MHz to acquire real-time B-mode ultrasound images of the tumor and surrounding hepatic or pancreatic tissue; delineating boundaries of the tumor on the acquired B-mode images and programming a plurality of focal ablation zones within the tumor volume; activating a therapeutic focused ultrasound mode of the catheter at 1-3 MHz and sequentially sonicating each programmed focal zone; monitoring cumulative thermal dose at each focal zone from acoustic backscatter data; and terminating sonication at each zone upon reaching a predetermined thermal dose threshold, wherein the imaging mode and therapeutic mode are performed without removing or repositioning the catheter.
[0059] In some implementations, the method further comprises administering ultrasound contrast microbubbles intravenously prior to the therapeutic mode to enhance acoustic energy deposition and reduce the acoustic power required for ablation, and monitoring passive cavitation emissions during sonication to detect and prevent inertial cavitation.CHZ-00225
[0060] In some implementations, the step of sonicating includes applying electronic focal steering to ablate a tumor volume up to 5 cm in maximum diameter by overlapping individual focal zones of 3-8 mm diameter without mechanical repositioning of the catheter.
[0061] In a tenth aspect, the disclosed subject matter provides a dual-frequency intravascular ultrasound transducer assembly for simultaneous diagnostic imaging and therapeutic ablation, comprising: a first linear array of at least 8 piezoelectric elements resonant at a first therapeutic frequency of 1-3 MHz, arranged with an element pitch of 0.4-0.7 mm in the azimuthal direction; a second linear array of at least 16 piezoelectric elements resonant at a second imaging frequency of 5-15 MHz, arranged with an element pitch of 0.2-0.3 mm in the azimuthal direction; wherein the first and second arrays are co-located on a common substrate within a total axial footprint of 40 mm or less and an outer diameter of 5 mm or less, making the assembly suitable for deployment within a human blood vessel; an acoustic impedance matching layer covering both arrays; and a backing material providing at least -35 dB attenuation of backward-propagating acoustic energy.
[0062] In some implementations, the first and second arrays are interleaved in a rowcolumn configuration, with the piezoelectric elements of the second linear array disposed between adjacent piezoelectric elements of the first linear array in the azimuthal direction, enabling spatially coincident imaging and therapeutic beam patterns.
[0063] In some implementations, the piezoelectric elements of both arrays are fabricated from PMN-PT single crystal and are individually addressable through independent coaxial signal conductors, enabling independent phase and amplitude control for real-time electronic focus steering of both an imaging beam and a therapeutic beam.
[0064] In some implementations, the transducer assembly further comprises a curved acoustic lens providing a fixed geometric focal length of 20-40 mm in an elevation dimension, wherein electronic steering of both the imaging and therapeutic beams is performed in an azimuthal dimension over a range of ±45° from a longitudinal axis of the assembly.
[0065] In some implementations, the at least one ultrasound transducer element comprises a multi-element phased array in which each element is individually addressable to enable electronic beam steering and focal depth variation from 5 mm to 60 mm from a longitudinal axis of the catheter body without mechanical repositioning of the catheter body.
[0066] In some implementations, the at least one transducer element comprises a phased array configured to electronically steer an acoustic focus in an azimuthal dimensionCHZ-00225over a range of ±25° and to a selectable focal depth of 5 mm to 50 mm from the sinus wall toward ipsilateral cerebral cortex.
[0067] In some implementations, the transducer array is configured to electronically steer an acoustic focus in the azimuthal dimension over a range of at least ±25° from the catheter longitudinal axis, enabling bilateral targeting of hippocampal structures from a single catheter position within the straight sinus.
[0068] In some implementations, the neurological condition is selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington’s disease, multiple sclerosis, spinal muscular atrophy, lysosomal storage disorders with CNS involvement, glioblastoma, epilepsy, traumatic brain injury, and CNS metastatic disease.
[0069] In some implementations, the therapeutic transgene is selected from the group consisting of: GBA for Parkinson’s disease or Gaucher’s disease with CNS involvement; SMN1 for spinal muscular atrophy; an HTT-silencing construct for Huntington’s disease; ASPA for Canavan disease; CLN2, CLN3, or CLN6 for neuronal ceroid lipofuscinoses (Batten disease); LRRK2 or SNCA for Parkinson’s disease; SOD 1 -targeting constructs for amyotrophic lateral sclerosis; progranulin (GRN) for frontotemporal dementia; and NAGLU for Sanfilippo syndrome type B.
[0070] In some implementations, the cell-based therapeutic is selected from the group consisting of: chimeric antigen receptor T cells (CAR-T) targeting a CNS tumor antigen; neural stem cell-derived progenitors for neurodegenerative disease; regulatory T cells for neuroinflammatory conditions; and induced pluripotent stem cell-derived dopaminergic neurons for Parkinson’s disease.
[0071] In some implementations, the control system is further configurable to operate in a sonodynamic therapy mode in which acoustic energy is delivered in combination with a systemically administered sonosensitizer agent (e.g., to achieve targeted cytotoxicity in CNS tumor tissue including glioblastoma, CNS metastases, or primary CNS lymphoma).
[0072] In some implementations, the control system is further configurable to operate in a sonothrombolysis mode in which moderate-intensity pulsed focused ultrasound is delivered e.g., for treatment of cerebral venous sinus thrombosis).
[0073] In some implementations, the therapeutic agent is a monoclonal antibody targeting a CNS pathological protein aggregate selected from the group consisting of amyloid-beta, tau, alpha-synuclein, TDP-43, FUS, and huntingtin protein.CHZ-00225
[0074] In some implementations, the therapeutic agent is a recombinant enzyme selected for replacement therapy in a lysosomal storage disorder with CNS involvement, including but not limited to glucocerebrosidase for Gaucher’s disease, iduronate-2-sulfatase for Hunter syndrome, alpha-L-iduronidase for Hurler syndrome, and N-acetylglucosaminidase for Sanfilippo syndrome type B.
[0075] In some implementations, the acoustic window includes angular emission control configured to selectively direct acoustic energy output to a defined angular sector of a radial emission field by segmented activation of transducer sub-elements, mechanical rotation of a directional emitter, or incorporation of an asymmetric acoustic reflector or absorber within the catheter body. In some implementations, angular emission control is configured to direct acoustic energy as a directed arc of less than 360°.
[0076] In some implementations, the disclosed subject matter provides a coordinated intracranial focused ultrasound system comprising: a first catheter configured for deployment within the superior sagittal sinus and configured for radial or circumferential acoustic energy delivery to medial cortical structures; a second catheter configured for deployment within the straight sinus and comprising a multi-element curved phased array configured for focused acoustic energy delivery to hippocampal-entorhinal circuit structures at focal depths of 5 mm to 60 mm; and a coordinating control system configured to operate said first and second catheters simultaneously or sequentially during a single interventional procedure.
[0077] In some implementations, the disclosed subject matter provides a method for delivering focused acoustic energy to intracranial tissue using phased-array-guided intravascular ultrasound, comprising: positioning a catheter comprising a multi-element phased array within a dural venous sinus or intracranial vein; electronically steering an acoustic focus of the multi-element phased array to a target tissue depth of 5 mm to 60 mm from the catheter axis; delivering pulsed or continuous acoustic energy to the target tissue; and modulating energy delivery parameters in real time based on feedback from at least one of a passive cavitation detection subsystem, a temperature sensor, or a proximity sensor.
[0078] In some implementations, the catheter body is constructed from nonferromagnetic materials and signal transmission is provided via fiberoptic pathways, such that the system is compatible with magnetic resonance imaging environments.
[0079] In some implementations, the at least one ultrasound transducer element comprises a multi-element phased array in which each element is individually addressable to enable electronic beam steering and focal depth variation from 5 mm to 60 mm from theCHZ-00225catheter axis without mechanical repositioning of the catheter body, with an azimuthal steering range of at least ±25°.
[0080] In some implementations, the system further comprises an electronic beamforming system operatively coupled to the at least one ultrasound transducer element, configured to electronically steer a therapeutic focal zone to a selectable depth from a longitudinal axis of the catheter body without physical repositioning of the catheter, and a processor executing a closed-loop thermal dosimetry algorithm configured to estimate cumulative thermal dose at the focal zone from acoustic backscatter data and to terminate energy delivery upon reaching a predetermined thermal dose threshold.
[0081] In some implementations, the at least one transducer element is configured to deliver acoustic energy over a radial emission coverage range of up to 5 cm from the catheter body.
[0082] In some implementations, the therapeutic agent is a gene therapy vector carrying a therapeutic transgene, wherein the therapeutic transgene is selected from: a transgene encoding an enzyme whose deficiency causes a CNS -manifesting enzyme deficiency disorder; or an inhibitory nucleic acid construct targeting a gene product associated with pathological protein aggregation in a neurodegenerative disease.
[0083] The accompanying drawings, which are incorporated in and constitute part of this specification, are included to illustrate and provide a further understanding of the method and system of the disclosed subject matter. Together with the description, the drawings serve to explain the principles of the disclosed subject matter.BRIEF DESCRIPTION OF THE DRAWINGS
[0084] The accompanying drawings, which are incorporated into and constitute a part of this specification, illustrate various implementations and together with the description, serve to explain the principles of the disclosed subject matter. It is to be understood that in some instances various aspects of the described implementations may be shown exaggerated or enlarged to facilitate an understanding of the described implementations. In the drawing, like reference characters generally refer to like features, functionally, and / or structurally similar elements throughout the various drawings. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the teachings. The drawings are not intended to limit the scope of the present teachings in any way.
[0085] FIG. 1 is a cross-sectional schematic view of an implementation of a intravascular ultrasound catheter system deployed in the superior sagittal sinus (SSS).CHZ-00225
[0086] FIG. 2 is a sagittal view of an implementation of a catheter system deployed longitudinally in the SSS, showing radial acoustic emission zones covering the posterior cingulate cortex (PCC), precuneus, anterior cingulate cortex (ACC), medial prefrontal cortex (mPFC), paracentral lobule, and superior parietal lobule within a 5 cm coverage radius, with the hippocampus shown outside the emission zone for anatomical context.
[0087] FIG. 3 is a cross-sectional schematic view of an implementation of a focused ultrasound catheter deployed in the straight sinus, and an associated material and specification table.
[0088] FIG. 4 is a schematic view of an endovascular venous access route, and including a step-by-step procedure overlay.
[0089] FIG. 5 is a coronal slice schematic illustrating an acoustic beam path from the straight sinus catheter to hippocampal targets, an acoustic parameter table, and a microbubble protocol.
[0090] FIG. 6 is a flowchart of an implementation of a passive cavitation detection (PCD) closed-loop control algorithm.
[0091] FIG. 7 is a schematic view of an implementation of a treatment zone protocol, with a procedure summary table.
[0092] FIG. 8 is a coronal cross-sectional view at the L1-L2 vertebral level showing an implementation of a catheter system deployed in the inferior vena cava (IVC), with therapeutic beam and imaging beam paths directed toward a hepatic tumor and a pancreatic tumor, with the liver and pancreas shown for anatomical context.
[0093] FIG. 9 includes transverse cross-sectional views at the shaft section and transducer zone of an implementation of a catheter system, showing the lumen layout including guidewire lumen, irrigation lumen, coaxial signal cables, and transducer elements.
[0094] FIG. 10 is a longitudinal section of an implementation of a catheter system.
[0095] FIG. 11 is an exploded cross-sectional view of an implementation of a dualfrequency transducer stack.
[0096] FIG. 12 is a system block diagram showing an implementation of an electronic system architecture of a catheter system.DETAILED DESCRIPTION
[0097] The various concepts introduced above and discussed in greater detail below may be implemented in a number of ways, as the described concepts are not limited to any particular manner of implementation.CHZ-00225
[0098] Reference will now be made in detail to implementations of the present disclosure, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
[0099] References herein to positions of elements (e.g., “top”, “bottom”) are merely used to describe the orientation of various elements in the FIGURES. It should be noted that the orientation of various elements may differ according to other implementations, and that such variations are intended to be encompassed by the present disclosure.
[0100] The term “about” means a range of values inclusive of the specified value that a person of ordinary skill in the art would reasonably consider to be comparable to the specified value. In some implementations, “about” means within a standard deviation using measurements generally accepted by a person of ordinary skill in the art. In some implementations, “about” means ranging up to ±10% of the specified value. In some implementations, “about” means ranging up to ±5% of the specified value. In some implementations, “about” means the specified value.
[0101] As used herein, the term “distal” refers to the end or portion of the catheter body that is advanced into and positioned within the patient’s vasculature, and that is farthest from the operator during use. The term “proximal” refers to the opposite end or portion of the catheter body that remains nearest to the operator and is configured for connection to external systems, including, for example, the control unit, power source, fluid delivery apparatus, and signal processing hardware.
[0102] The disclosed subject matter relates to endovascular medical devices and therapeutic ultrasound systems, and more particularly to catheter-integrated ultrasound delivery systems designed for use within intracranial arteries and dural venous sinuses, including the superior sagittal sinus (SSS) and the straight sinus (sinus rectus).
[0103] Conventional ultrasound systems used for neuromodulation, blood-brain barrier (BBB) modulation, and thermal therapy are primarily extracranial. These systems rely on transcranial delivery, which is fundamentally limited by skull attenuation, acoustic impedance mismatch, and complex beamforming requirements. While catheter-based ultrasound systems exist for peripheral vascular applications such as sonothrombolysis or intravascular imaging (IVUS), they are not designed or optimized for the anatomy, physics, or access constraints of the intracranial vasculature.
[0104] Skull heterogeneity distorts beam shape, degrades focus, and necessitates MR-based targeting or phase correction, hindering the precision, depth, and adaptability ofCHZ-00225transcranial ultrasound therapies. Moreover, existing peripheral catheter-based ultrasound systems typically emit ultrasound axially or directionally within large-diameter vessels, with limited compatibility for deep-brain targeting or radial cortical energy delivery. Intracranial arteries and dural venous sinuses are in close proximity to functionally critical brain structures, including the sensorimotor cortex, thalamus, and hippocampus, yet current endovascular devices lack the capability to deliver controlled acoustic energy radially toward these targets without extensive beam steering or system complexity. Existing catheter systems may not integrate radial emission, real-time sensing, drug co-delivery, and thermal modulation in a form factor compatible with intracranial navigation.
[0105] The superior sagittal sinus (SSS) runs along the superior midline from the frontal pole to the occipital pole and overlies the medial prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex (PCC), precuneus, and paracentral lobule, regions that represent the highest amyloid burden in early Alzheimer's disease (illustrated in FIG. 2). The straight sinus (sinus rectus) lies in close proximity to the hippocampus, entorhinal cortex, amygdala, and posterior thalamus, the structures most critically affected in Alzheimer's disease dementia.
[0106] Blood-brain barrier (BBB) modulation via focused ultrasound (FUS) in combination with systemically administered microbubble contrast agents has emerged as a clinically validated strategy for enhancing CNS drug delivery. No existing catheter system delivers focused therapeutic ultrasound from within a dural venous sinus for the purpose of BBB modulation and drug delivery.
[0107] Anti-amyloid immunotherapy (e.g., lecanemab, donanemab) requires systemic intravenous administration, with BBB penetration as a rate-limiting step. Enhanced BBB permeability at hippocampal and entorhinal targets via intravascular FUS from the straight sinus could substantially increase local drug concentration, potentially reducing systemic dose, adverse effects such as amyloid-related imaging abnormalities (ARIA), and treatment burden while improving efficacy.
[0108] In the field of hepatic and pancreatic oncology, hepatocellular carcinoma (HCC) affects approximately 900,000 patients annually worldwide and is the third leading cause of cancer-related mortality. Pancreatic ductal adenocarcinoma carries a 5-year survival of less than 12%, with most cases diagnosed at an unresectable stage. Existing ablative modalities, radiofrequency ablation (RFA), microwave ablation (MW A), and cryoablation, require direct needle puncture through the parenchyma, limiting applicability for tumors adjacent to major vessels or in patients with coagulopathy or ascites.CHZ-00225
[0109] External high-intensity focused ultrasound (HIFU) systems deliver ablative energy transcutaneously, but require a clear acoustic window free of bowel gas, ribs, and overlying subcutaneous tissue. These constraints render approximately 30-40% of liver and pancreatic tumors inaccessible by extracorporeal approaches. Intravascular HIFU catheter systems have been demonstrated in preclinical models, achieving 5-10 mm perivascular ablation lesions from the IVC under MRI thermometry guidance. However, no prior system combines real-time B-mode ultrasound visualization with therapeutic HIFU delivery in a single intravascular catheter. MRI guidance imposes logistical constraints (MRI suite access, susceptibility artifacts from metallic guidewires, cost, and procedure time) that limit clinical adoption.
[0110] There is a need for a system that combines an intravascular catheter platform with focused ultrasound emission within the dural venous sinuses, passive cavitation detection, closed-loop control, drug delivery lumens, and anatomically targeted BBB modulation for neurological disease. There is a further need for a minimally invasive, intravascular approach to ablation of solid tumors in the liver, kidney, and pancreas that does not require percutaneous needle puncture, external acoustic windows, or MRI-guided thermometry.
[0111] The disclosed subject matter addresses the need for localized, skullindependent delivery of diagnostic or therapeutic acoustic energy to brain structures from within the cerebral vasculature, including by providing a catheter system capable of emitting acoustic energy radially or circumferentially from within intracranial arteries or veins toward adjacent neural tissue. The disclosed subject matter pertains to applications including neuromodulation, thermal ablation, blood-brain barrier modulation, drug delivery, gene therapy, cell therapy, sonodynamic therapy, and intracranial vessel-targeted interventions. In particular, the disclosed subject matter may enable radial, circumferential, or focused emission of acoustic energy toward adjacent neural tissue from within large-caliber cerebral veins or arteries, overcoming limitations of extracranial systems. In some implementations, the catheter system is configured to target the hippocampal-entorhinal circuit via the straight sinus for treatment of Alzheimer’s disease and related amyloid-mediated disorders.
[0112] The BBB modulation platform described herein has broad applicability to delivery of therapeutic agents across multiple classes, as described in greater detail in paragraph
[0109] below, including without limitation: (a) small-molecule CNS drugs, (b) biologic therapeutics including monoclonal antibodies, (c) viral gene therapy vectors including adeno-associated vims (AAV) serotypes, (d) non-viral nucleic acid deliveryCHZ-00225systems including lipid nanoparticles carrying mRNA, siRNA, or CRISPR constructs, (e) cell-based therapies, and (f) diagnostic imaging agents.
[0113] In some implementations, the disclosed subject matter provides a dual-mode intravascular catheter system combining real-time B-mode ultrasound imaging with therapeutic high-intensity focused ultrasound ablation, deployable within the inferior vena cava or hepatic venous system for targeted treatment of hepatocellular carcinoma, hepatic metastases, renal cell carcinoma, and pancreatic adenocarcinoma from within the bloodstream, overcoming limitations of both extracorporeal HIFU and conventional percutaneous ablative modalities.
[0114] In brief overview, the disclosed subject matter may include four subsystems: (1) an elongated flexible catheter body configured for navigation through vasculature (e.g., intracranial vasculature, extracranial vasculature, dural venous sinuses, the inferior vena cava, hepatic veins, renal veins, and other major venous or arterial conduits); (2) one or more ultrasound transducer elements integrated within or at the distal portion of the catheter body, configurable for radial, circumferential, focused, or axial acoustic emission; (3) an acoustic window formed in the catheter wall or at the catheter tip, composed of a low-acoustic-attenuation material; and (4) a control system operatively connected to the one or more transducer elements for selection of operating parameters, closed-loop feedback, and treatment planning.
[0115] The disclosed subject matter may include one or more optional subsystems and features. Such subsystems and features may include, for example, one or more drug delivery lumens or channels, cooling lumens, passive cavitation detection elements, fiberoptic signal pathways, deployable scaffolding, positional sensing systems, closed-loop thermal feedback systems, real-time imaging co-registration abilities, and frequency tunability e.g., over a range from about 1 kHz to about 100 MHz, including in some implementations from about 20 kHz to about 20 MHz).
[0116] In a first aspect, the disclosed subject matter provides a catheter system for therapeutic or diagnostic energy delivery from within intracranial vasculature, comprising an elongated flexible catheter body, at least one ultrasound transducer element, an acoustic window, and a control system; wherein the transducer is configured to emit acoustic energy radially outward, circumferentially, or in a focused beam toward adjacent brain tissue, without requiring external beam steering or transcranial propagation through the skull.
[0117] In a second aspect, the disclosed subject matter provides a method for bloodbrain barrier modulation comprising: positioning a focused ultrasound catheter within a duralCHZ-00225venous sinus; administering microbubble contrast agent systemically; delivering pulsed focused ultrasound energy at parameters sufficient to produce stable cavitation and transiently increase BBB permeability; and administering a therapeutic agent systemically within a defined time window following BBB modulation.
[0118] In a third aspect, the disclosed subject matter provides a catheter system configured for deployment within a straight sinus and for BBB-opening targeting the hippocampal-entorhinal circuit. The catheter system may include a multi -element curved piezoelectric array, integrated passive cavitation detection, and an irrigation lumen for thermal management.
[0119] In a fourth aspect, the disclosed subject matter provides a catheter system configured for deployment within the SSS and for radial and / or circumferential acoustic delivery to medial cortical structures, including the PCC, precuneus, ACC, and sensorimotor cortex, operable in thermal ablation mode, neuromodulation mode, BBB opening mode, or sonodynamic therapy mode.
[0120] In various aspects, the systems and methods described herein eliminate reliance on extracranial beamforming, phased-array control, or skull-dependent acoustic paths by delivering energy locally from within the vasculature. The systems and methods described herein integrate a transducer, acoustic window, and control system into a single catheter device, optionally including drug delivery, thermal feedback, and real-time modulation of acoustic parameters, enabling therapeutic modalities such as neuromodulation, thermal ablation, sonodynamic therapy, and blood-brain barrier modulation using a miniaturized, steerable, and optionally anchored catheter system. In some implementations, the catheter system is configured for radial or circumferential acoustic emission from within intracranial arteries or veins and operates without requiring beam steering or phased-array control. In such implementations, effective energy delivery to perivascular neural tissue may be achieved through anatomical proximity alone, without electronic focusing, phase correction, or phased-array signal processing. In other implementations, as described herein, electronic beam steering may be employed to reach targets at greater depths from the vascular conduit.
[0121] Referring now to FIG. 1, a cross-sectional schematic view of an intravascular ultrasound catheter system having a catheter body 100 is shown. FIG. 1 depicts the intravascular ultrasound catheter system deployed in the superior sagittal sinus (SSS), showing the catheter body 100 centered in the SSS lumen. In some implementations, the SSS lumen has a width of about 8 mm, although it should be appreciated that the dimensions ofCHZ-00225the SSS may vary among individuals and along the anterior-posterior extent of the sinus. The catheter body 100 may be navigated through intracrnial arteries or dural sinuses.
[0122] The catheter body 100 may have an elongated tubular configuration and may be cylindrical in shape, although other cross-sectional shapes (e.g., oval, elliptical, polygonal, irregular) are also contemplated. The catheter body includes a distal portion and a proximal portion. The distal portion may house one or more therapeutic and / or diagnostic components, including, for example, at least one ultrasound transducer element 102, an acoustic window 104, passive cavitation detection elements, or an atraumatic tip. The proximal portion may include, for example, a hub, a connector assembly, and one or more interfaces for guidewire access, irrigation delivery, signal transmission, and operator control.
[0123] In some implementations, the catheter body 100 includes an outer sheath formed from a medical-grade polyether-block amide copolymer {e.g., PEBAX 72 Shore D durometer). In some implementations, the catheter body 100 has an outer diameter (OD) of 5-6 French (Fr), corresponding to between about 1.67 mm and about 2 mm.
[0124] In some implementations, the catheter body 100 includes one or more sensors disposed within the catheter body, embedded in wall of the catheter body (catheter wall), and / or mounted on a surface thereof e.g., outer surface of the catheter body). Such sensors may include, for example, temperature sensors, acoustic sensors {e.g., passive cavitation detection elements), positional sensors, pressure sensors, and / or flow sensors.
[0125] One or more transducer elements 102 may be disposed within the catheter body 100, embedded in the catheter wall, and / or mounted on a surface thereof {e.g., interior surface of the catheter body). In some implementations, a transducer array 122 includes the one or more transducer elements 102. For example, the transducer array 122 may be a curved array of 8 discrete transducer elements, each fabricated from a piezoelectric material, such as lead magnesium niobate-lead titanate (PMN-PT) single-crystal material. In some implementations, the transducer elements 102 may be fabricated using capacitive micromachined ultrasound transducer (CMUT) or piezoelectric micromachined ultrasound transducer (PMUT) architectures, which support catheter-scale form factors and MHz-range operation.
[0126] The one or more transducer elements 102 may emit acoustic energy through an acoustic window 104 {e.g., a low-attenuation membrane or acoustic transmissive material). The acoustic window 104 may be integrated into the catheter wall. In some implementations, a distal portion of the catheter body 100 houses one or more transducer elements 102. In some implementations, each transducer element 102 of the transducer arrayCHZ-00225122 is individually addressable, thereby allowing for electronic phasing of the driving signals to steer and / or focus an acoustic beam at a desired focal point (e.g., a focal point within the brain parenchyma).
[0127] In some implementations, the transducer elements 102 direct orthogonally outward (z.e., in a radial mode), focus acoustic energy to a predetermined depth, and / or sweep acoustic energy circumferentially e.g., via mechanical rotation and / or electronic beam steering). In some implementations, radial emission may be configured as about 360° or as a directed arc (less than 360°). Radiated ultrasound energy may propagate outward through concentric anatomical layers including sinus lumen 108, vein wall 110, dura mater 112, cerebrospinal fluid (CSF) 114, cerebral cortex 118, and white matter 120. In some implementations, the dura mater 112 has an effective thickness along the acoustic path of about 6 mm and represents a dominant acoustic loss layer, and the CSF 114 has an effective thickness of about 10 mm and is near-acoustically transparent.
[0128] In some implementations, the catheter system is operably coupled to a control system. The control system may include an external control unit or programmable console configured to control operation of the catheter system. The control system may be configured to adjust one or more operating parameters, including emission frequency, pulse duration, intensity, duty cycle, and treatment sequence e.g., in real time). In some implementations, the control system receives and processes sensor data from the one or more sensors of the catheter system including temperature measurements, cavitation spectral signatures (e.g., from passive cavitation detection elements), and positional feedback, and may perform closed-loop modulation of acoustic output based on the sensor data.
[0129] The control system may further include a user interface configured for procedure planning, real-time parameter adjustment during sonication, visualization of imaging data (e.g., from the transducer operating in imaging mode), display of thermal dosimetry data, and logging of treatment parameters and cavitation data for post-procedure analysis.
[0130] In some implementations, the control system is implemented as a dedicated hardware unit and / or as software executed on a general-purpose computing platform. The control system may communicate with the catheter system via wired and / or wireless data links, and power and control signals may be transmitted through the catheter shift via electrical conductors and / or fiberoptic pathways. The control system may further interface with external systems, including hospital information systems, for data integration and electronic medical record documentation.CHZ-00225
[0131] Although specific implementations are described herein with reference to particular anatomical targets, transducer configurations, and operating parameters, it is to be understood that the disclosed catheter system architecture is not limited to the specific combinations described. The catheter body, transducer elements, acoustic window, control system, drug delivery lumens, cooling lumens, fiberoptic pathways, scaffolding, and sensor subsystems may be combined, omitted, or substituted in various configurations. The disclosed systems may be deployed in any blood vessel of sufficient caliber to accommodate the catheter, including but not limited to intracranial arteries, dural venous sinuses, the inferior vena cava, hepatic veins, renal veins, and other major venous or arterial conduits. Operating frequencies, transducer materials, array geometries, and acoustic emission patterns may be varied to suit the specific clinical application, target tissue depth, and anatomical geometry.
[0132] Still referring to FIG. 1, and with additional reference to FIG. 2, the catheter body 100 may be navigated via jugular access through the sigmoid sinus and transverse sinus to the SSS. FIG. 2 depicts a sagittal view of the catheter body 100 deployed longitudinally in the SSS, illustrating radial acoustic emission zones extending outward from the catheter body. In some implementations, the emission zones cover a radial distance of up to about 5 cm and may encompass anatomical regions including the posterior cingulate cortex (PCC), precuneus, anterior cingulate cortex (ACC), medial prefrontal cortex (mPFC), paracentral lobule, and superior parietal lobule within a 5 cm coverage radius. The hippocampus is shown outside the emission zone for anatomical context. The PCC and precuneus may be associated with elevated amyloid burden in Alzheimer’s disease and may play a role in network-level propagation pathways, such as the default mode network.
[0133] In some implementations, the catheter system is operable in one or more therapeutic modes, including a BBB modulation mode, a thermal ablation mode, and a neuromodulation mode. In some implementations, the transducer array 122 is configured to operate at a frequency of about 700 kHz. In some implementations, the one or more transducer elements 102 is frequency -tunable across a range between about 1 kHz and about 100 MHz. In some implementations, the one or more transducer elements 102 is frequency-tunable across a range between about 20 kHz and about 20 MHz.
[0134] In a BBB modulation mode, the one or more transducer elements 102 may operate at frequencies between about 200 kHz and about 1.5 MHz, with mechanical index (MI) maintained between about 0.1 and about 0.7 and ISPTA at or below about 720 mW / cm2. In some implementations, the MI is maintained between about 0.2 and about 0.6. In someCHZ-00225implementations, the one or more transducer elements 102 operate at about 700 kHz with a mechanical index (MI) between about 0.35 and about 0.55. In some implementations, pulsed sonication is delivered concurrently with or following systemic administration of microbubble contrast agent.
[0135] In a thermal ablation mode, the one or more transducer elements 102 may operate at frequencies between about 1 MHz and about 10 MHz for HIFU. In some implementations, the one or more transducer elements 102 operate at frequencies between about 1 MHz and about 10 MHz using continuous or high-duty -cycle pulsed waveforms, targeting HIFU-range intensities at the focal zone. This mode may be suitable for ablation of cortical seizure foci, vascular malformations, or cortical tumors accessible from the superior midline. When directed at neural tissue targets such as cortical seizure foci, this mode may also be referred to as thermal neuroablation, and is distinguished from neuromodulation in that it delivers destructive acoustic energy sufficient to produce coagulative necrosis or permanent tissue modification.
[0136] Unlike thermal ablation, which targets irreversible tissue destruction, neuromodulation delivers sub-therapeutic-intensity acoustic energy to produce reversible changes in neural excitability without permanent tissue injury. In a neuromodulation mode, the one or more transducer elements 102 may operate at frequencies less than about 2 MHz with a spatial-peak temporal-average intensity (ISPTA) of less than about 100 mW / cm2. In some implementations, the one or more transducer elements 102 operate at low intensities (ISPTA < about 100 mW / cm2) with low-frequency pulsed waveforms (between about 500 kHz and about 2 MHz). In some implementations, such neuromodulation targets reversible modulation of neural excitability in medial cortical circuits, including components of the default mode network.
[0137] In contrast to the SSS configuration described above with reference to FIG. 1 and FIG. 2, which employs radial or circumferential acoustic emission to deliver energy broadly to superficial medial cortical structures, the straight sinus (SS) configuration described below with reference to FIG. 3 and FIG. 4 is optimized for focused acoustic energy delivery to deep medial temporal structures, including the hippocampal-entorhinal circuit. Whereas the SSS lumen is a large-caliber, generally circular conduit (about 6.0 mm to about 9.9 mm) accommodating a higher-caliber catheter with radial emission geometry, the straight sinus presents a smaller-caliber (about 4 to about 6 mm), generally triangular cross-section which can require a distinct catheter profile and a multi -element curved phased array configured for electronic beam steering to reach targets at depths of about 5 mm to about 60CHZ-00225mm from the sinus lumen (e.g., about 10 mm to about 55 mm). This anatomical and geometric distinction may necessitate a different transducer architecture, catheter form factor, and acoustic delivery strategy, as described in the following paragraphs.
[0138] Referring now to FIG. 3, a cross-sectional schematic view of a focused ultrasound catheter deployed in the straight sinus is shown, illustrating the triangular sinus lumen geometry defined by dural sinus wall 310, with blood venous lumen 308 within. As shown in FIG. 3, the straight sinus lies in direct anatomical proximity to the hippocampus (body and posterior tail), entorhinal cortex, amygdala, posterior thalamus, and medial temporal structures at distances of about 15 mm to about 55 mm from the sinus lumen, within the steering range of a phased array optimized for this geometry. In various aspects, this proximity may make the straight sinus an anatomically privileged vascular corridor for focused acoustic energy delivery to structures central to Alzheimer’s disease pathophysiology.
[0139] In some implementations, the catheter body 100 includes an outer sheath formed from a medical-grade polyether-block amide copolymer (e.g., PEBAX 72 Shore D durometer). In some implementations, the catheter body 100 has an outer diameter (OD) of about 4.5 mm or less. In some implementations, the catheter body 100 has an outer diameter (OD) between about 3.0 mm (9 Fr) and about 3.5 mm. In some implementations, the catheter body includes an atraumatic distal tip. In some implementations, the catheter body 100 has a tip OD between about 1.5 mm and about 3.0 mm.
[0140] FIG. 3 further depicts the transducer array 122, which can be configured to emit focused beam trajectories 302 to bilateral hippocampal targets 304 at a focal depth of about 35 to about 55 mm from the transducer array 122. In some implementations, the transducer array 122 includes a multi -element curved piezoelectric array configured to conform to the triangular cross-section of the sinus lumen.
[0141] In some implementations, the transducer array 122 includes a plurality of transducer elements 102 formed of a piezoelectric material, such as lead magnesium niobate-lead titanate (PMN-PT) single crystal material, having an electromechanical coupling coefficient (kt) greater than about 0.65 (e.g., 0.7). In some implementations, the plurality of transducer elements are arranged with about 0.8 mm pitch over an axial length of about 12 mm, with each transducer element 102 having an aperture of about 2.5 mm. In some implementations, the plurality of transducer elements 102 includes 8 transducer elements.
[0142] In some implementations, the transducer array 122 includes a backing layer disposed behind the plurality of transducer elements 102. The backing layer may include aCHZ-00225tungsten-loaded epoxy material (W-epoxy) configured to attenuate backward-propagating acoustic energy, for example providing an attenuation of at least about -35 dB, and in some implementations about -40 dB, thereby reducing reflections and improving forward acoustic transmission and bandwidth. In some implementations, the transducer array 122 includes one or more signal transmission lines, such as micro-coax cables (e.g., micro-coax 50Q x 8 channels), configured to independently drive and / or receive signals from the plurality of transducer elements 102.
[0143] In some implementations, the transducer array 122 operates at a frequency of about 700 kHz, with a frequency range between about 650 kHz and about 750 kHz. In some implementations, the pulse duration is about 10 ms with a pulse repetition frequency (PRF) of about 1 Hz, corresponding to about a 1% duty cycle, wherein the pulse duration defines a time interval during which acoustic energy is transmitted per pulse.
[0144] In some implementations, the transducer array 122 is configured for electronic phase steering to enable focal depth variation from about 5 mm to about 60 mm without catheter repositioning. In some implementations, the focal depth range is from about 10 mm to about 55 mm. In some implementations, the focal depth range is from about 10 mm to 60 mm. In various aspects, this can enable coverage of the full hippocampal body and posterior entorhinal cortex. In some implementations, the steering range is about ±25° in an azimuthal dimension.
[0145] In some implementations, the acoustic focus has a spatial extent between about 3 mm and about 4 mm full width at half maximum (FWHM) in an axial direction and between about 2 mm and about 3 mm FWHM in a lateral direction at a focal depth of about 30 mm. In some implementations, the ISPTA is at or below about 720 mW / cm2. In some implementations, the MI is between about 0.35 and about 0.55.
[0146] In some implementations, the catheter system includes an irrigation system configured to deliver a fluid, such as heparinized saline. The irrigation system may be configured to provide cooling of the transducer array 122 during operation, reduce thrombus formation, improve acoustic coupling between the transducer array 122 and surrounding tissue or fluid, and / or maintain patency of the surrounding vasculature. In some implementations, the irrigation fluid is delivered through one or more lumens of the catheter body 100 and may be controlled to provide a continuous or intermittent flow.
[0147] Still referring to FIG. 3, and with additional reference to FIG. 4, the catheter body 100 may be navigated via an endovascular venous access route extending from the right internal jugular vein (IJV) to sigmoid sinus, to transverse sinus, to torcular Herophili, andCHZ-00225into straight sinus. The right IJV 401 may have an outer diameter of about 12 mm and may be accessed via a standard introducer sheath (e.g., about 9 Fr). The sigmoid sinus 402 may have an outer diameter of about 9 mm, and may exhibit a tortuosity of at least about 90 degrees. The transverse sinus 403 may have an outer diameter of about 8 mm. The torcular Herophili 404 may have an outer diameter of about 12 mm.
[0148] FIG. 4 illustrates a schematic view of an endovascular venous access route for the straight sinus access. In some implementations, the catheter body 100 is advanced along a navigation pathway that proceeds from the right IJV 401 to the sigmoid sinus 402, to the transverse sinus 403, to the torcular Herophili 404, and into the straight sinus 405. In some implementations, the vein of Galen 406 represents a distal navigation limit of the catheter body 100, beyond which the catheter body 100 may not be advanced. In some implementations, the catheter body 100 has a working length within the straight sinus between about 38 and about 45 mm.
[0149] The navigation pathway may include about a 90-degree angulation at the torcular Herophili 404. Navigation across this angulation and through the transverse sinus 403 may be facilitated by a guidewire separate from the catheter body 100, the guidewire being configured intravascular navigation and, in some embodiments, including a hydrophilic coating or hydrophilic distal tip to reduce friction and improve trackability through the angulated anatomy. The catheter body 100 may likewise include a hydrophilic coating or hydrophilic distal tip to facilitate advancement along the guidewire across the angulation.
[0150] In operation, the catheter body 100 may be advanced using endovascular techniques over the guidewire to traverse the angulation at the torcular Herophili 404, the guidewire being receivable within a lumen of the catheter body 100 and remaining separate therefrom. In some implementations, the guidewire includes a 0.035-inch hydrophilic guidewire. The guidewire can be advanced from the jugular access to the torcular Herophili 404, and may then be exchanged to an atraumatic microwire e.g., about a 0.018-inch atraumatic J-tip microwire) to facilitate controlled entry into the straight sinus 405 beyond the angulation.
[0151] Catheter position may be confirmed using anteroposterior and / or lateral fluoroscopy, for example via one or more integrated radiopaque markers e.g., platinumiridium radiopaque markers) disposed on the catheter body 100. MRI co-registration may be used to enable pre-procedural planning and three-dimensional anatomical targeting.
[0152] Referring now to FIG. 5, a coronal slice schematic illustrating an acoustic beam path from the catheter body 100 deployed in the straight sinus to hippocampal targets isCHZ-00225shown. More generally, the acoustic propagation, attenuation, and focal zone characterization principles described with reference to FIG. 5 may be applicable to any catheter implementation described herein operating within any vascular conduit, with appropriate adjustment of tissue layer thicknesses and attenuation coefficients for the target anatomy. In some implementations, the total acoustic path length from the transducer array 122 to the hippocampal target is about 58 mm (e.g., at an operating frequency of about 700 kHz). As shown in FIG. 5, the acoustic path includes multiple anatomical layers, each contributing to attenuation.
[0153] Proceeding from the transducer array 122 toward the target e.g., left to right in FIG. 5), the acoustic path may include: the sinus lumen (blood) with a thickness of about 8 mm and an attenuation of about 3.6 dB; dural wall with a thickness of about 6 mm and an attenuation of about 8.4 dB, which may be the dominant attenuating layer in the acoustic path; cerebrospinal fluid (CSF) space with a thickness of about 10 mm and an attenuation of about 0 dB (acoustically transparent); cortex and white matter with a combined thickness of about 22 mm and an attenuation of about 27.7 dB; and deep grey matter (hippocampus) with a thickness of about 12 mm and a cumulative attenuation of about 29.6 dB. In some implementations, the total path attenuation is about 69 dB.
[0154] In some implementations, BBB modulation is achieved via the interaction of pulsed focused ultrasound (pFUS) delivered by the transducer array 122 with systemically administered microbubble contrast agents. Microbubbles are gas-filled microspheres that, when exposed to pulsed ultrasound at MI values between about 0.2 and about 0.6, undergo stable oscillation (stable cavitation) within the cerebral microvasculature. Such oscillation may produce localized mechanical effects, including microstreaming and transient disruption of endothelial tight junctions, resulting in reversible paracellular transport enhancement across the blood-brain barrier. The resulting transient increase in BBB permeability may enable systemically administered therapeutic agents to reach brain parenchyma at concentrations that would not be achievable under physiological BBB conditions.
[0155] In some implementations, the microbubble agent includes perflutren lipid microspheres e.g., Definity). In some implementations, the microbubble agent is administered as an intravenous bolus at a dose of about 0.2 mL / kg, with timing of about 30 seconds before each treatment zone. In alternative implementations, microbubbles are administered as a continuous infusion at about 7.2 pL / kg / min. The microbubble diameter may be about 1.1 to about 3.3 pm, with a resonant frequency of about 1 to about 3 MHz.CHZ-00225
[0156] At a focal zone within the hippocampus (e.g., as shown in FIG. 5), the transducer array 122 may achieve a focal spot size of about 3 mm to about 4 mm FWHM in an axial direction and about 2 mm to about 3 mm FWHM in a lateral direction at about 30 mm focal depth. In some implementations, the focal pressure is between about 0.3 MPa and about 0.45 MPa with microbubble augmentation, and the MI is between about 0.35 and about 0.55. In some implementations, a BBB opening threshold is about 0.25 MPa with microbubble augmentation, and the damage threshold is greater than about 0.70 MPa. The safety margin may be about 2 times the ratio of the opening threshold to the damage threshold.
[0157] In some implementations, the transducer array 122 operates at a duty cycle of about a 1% (e.g., about 10 ms pulse duration, about 1 Hz PRF), and the ISPTA of the transducer array 122 is maintained at or below about 720 mW / cm2at the focal zone. In some implementations, the electronic phase steering of the transducer array 122 provides a steering range of about ±25° in an azimuthal dimension and a focal depth range of about 10 to about 60 mm. In some implementations, the focal depth range is about 10 to about 55 mm.Estimated temperature rise may be about 0.8 degrees Celsius at the focal zone and about 0.3 degrees Celsius at the vessel wall, both within reversible limits. In some implementations, thermal dose (CEM43) at the focal zone is maintained below about 0.3.
[0158] Referring now to FIG. 6, a flowchart of a passive cavitation detection (PCD) closed-loop control algorithm is shown. Although described with reference to the straight sinus configuration and FIG. 6, the PCD-based closed-loop control architecture is applicable to any catheter implementation described herein, including the SSS, IVC, and hepatic vein configurations. In some implementations, the catheter body 100 includes at least two passive cavitation detection (PCD) elements co-located on the catheter body 100 adjacent to the transducer array 122. In some implementations, the PCD elements receive acoustic emissions from the treatment zone during each sonication burst and transmit the acoustic data to the control system. The control system may process the received acoustic data to perform closed-loop modulation of an acoustic output of the transducer array 122 based on the detected cavitation signatures.
[0159] As illustrated in the flowchart of FIG. 6, the closed-loop control algorithm distinguishes between stable cavitation and inertial cavitation based on the spectral content detected by the PCD elements. In some implementations, the control system performs realtime fast Fourier transform (FFT) analysis of the acoustic emission spectrum received by theCHZ-00225PCD elements during each sonication burst (e.g., about 10 ms burst) of the transducer array 122 (e.g., at about 700 kHz), enabling rapid spectral characterization of the cavitation signature on a burst-by -burst basis. Detection of sub-harmonic frequency components e.g., f / 2 = about 350 kHz for about a 700 kHz primary frequency) may indicate stable cavitation, which may be a desired therapeutic regime for BBB opening. In some implementations, detection of ultra-harmonic frequency components (e.g., about 1.5f) may further confirm stable cavitation. Detection of broadband frequency emission may indicate inertial cavitation, which should be avoided.
[0160] Based on the detected cavitation signature, the control system may automatically adjust the acoustic power output of the transducer array 122. For example, detection of broadband noise elevation above a threshold of about 20 dB over baseline may cause the control system to reduce the output power of the transducer array 122 by about 30%, while detection of broadband elevation exceeding about 40 dB above baseline may trigger an immediate zone abort and power-off. In some implementations, the control system may increase the output pressure of the transducer array 122 by about 10% in the absence of sub-harmonic detection (f / 2). In some implementations, the control system enforces a maximum focal pressure limit of about 0.5 MPa. In some implementations, one or more thresholds associated with cavitation detection, acoustic output adjustment, and / or safety limits may be predetermined, empirically derived, or dynamically adjusted based on baseline measurements, patient-specific conditions, or treatment objectives.
[0161] In some implementations, a temperature interlock at about 42°C, monitored via at least one integrated thermocouple on at least one transducer element 102 of the transducer array 122, representative of a transducer temperature, may cause the control system to provide automatic power cutoff to the transducer array 122. In some implementations, the control system monitors irrigation flow rate and initiates a pause protocol if flow falls below about 0.3 mL / min.
[0162] In some implementations, the control system is configured to achieve and maintain stable cavitation during a majority of transmitted pulses within a treatment interval, for example in greater than about 80% of pulses delivered to a given treatment zone, as determined based on detected cavitation signatures. All cavitation detection spectral data and power adjustments may be logged by the control system for post-procedure review.
[0163] Referring now to FIG. 7, a schematic view of a treatment zone protocol is shown. Although described with reference to the straight sinus, the concept of sequential treatment zone sonication with combined electronic steering and mechanical repositioning isCHZ-00225broadly applicable to any catheter implementation described herein. In some implementations, the treatment zone protocol includes sequential sonication of a plurality of treatment zones along the straight sinus, in which the transducer array 122 delivers focused acoustic energy to anatomical targets adjacent to each zone. In some implementations, the treatment zones include: Zone 1 (about 0 to about 12 mm from the torcular Herophili 404) targeting the posterior cingulate cortex (PCC) and posterior hippocampal tail; Zone 2 (about 12 to about 25 mm from the torcular Herophili 404) targeting the hippocampus body and amygdala; Zone 3 (about 25 to about 38 mm from the torcular Herophili 404) targeting the anterior hippocampus and entorhinal cortex; and Zone 4, in which bilateral targeting of deep medial temporal structures is achieved using electronic steering of the transducer array 122. In some implementations, the electronic steering of the transducer array 122 provides a steering range of about ±25° in the azimuth dimension, enabling targeting of bilateral structures from a catheter position within or adjacent to the torcular Herophili 404. In some implementations, bilateral targeting in Zone 4 is performed simultaneously or sequentially using electronic steering without repositioning of the catheter body 100.
[0164] In some implementations, each treatment zone receives a defined period of sonication. In some implementations, each treatment zone receives about 120 seconds of sonication (e.g., about 120 pulses at about 10 ms pulse duration, pulse repetition frequency (PRF) about 1 Hz). In some implementations, the catheter body 100 is repositioned between adjacent treatment zones by a pull-back maneuver of about 4 mm. In some implementations, a total active sonication time of about 12 minutes is achieved across the plurality of treatment zones. The treatment zone protocol may combine electronic steering, accomplished via phased array beamforming of the transducer array 122, with mechanical repositioning of the catheter body 100 through the pull-back maneuver.
[0165] In some implementations, a full treatment protocol includes the following steps. In some implementations, pre-procedure planning is performed, which may include magnetic resonance imaging (MRI) of the brain and MR venography within about 7 days prior to treatment, and treatment targets may be pre-planned on treatment planning software. Intravenous access and sedation may be established, and heparinization may be maintained e.g., activated clotting time (ACT) of about 250 to about 300 seconds). In some implementations, vascular access is obtained by puncturing the right IJV and placing an introducer sheath e.g., a 9 Fr sheath). A guidewire (e.g., about a 0.035-inch hydrophilic guidewire) may be advanced to the sigmoid sinus, transverse sinus, and torcular Herophili. The guidewire may then be exchanged for a microwire (e.g., about a 0.018-inch atraumatic J-CHZ-00225tip microwire) for straight sinus entry, and the catheter body 100 may be advanced under fluoroscopic guidance. Catheter position may be confirmed by anteroposterior (AP) and / or lateral fluoroscopy using integrated radiopaque markers (e.g., platinum-iridium radiopaque markers). Irrigation flow (e.g., about 1 mL / min heparinized saline) may be confirmed prior to sonication.
[0166] In some implementations, a sonication phase is initiated by administering a microbubble contrast agent (e.g., Definity at about 0.2 mL / kg) as an intravenous bolus about 30 seconds before the Zone 1. The transducer array 122 may deliver about 120 bursts at about 10 ms at about 1 Hz across the plurality of treatment zones, with the PCD elements monitoring cavitation signatures throughout the sonication phase and transmitting the received acoustic data to the control system. In some implementations, bilateral electronic steering of about ±25° is employed by the control system for Zone 4.
[0167] In some implementations, following completion of the sonication phase and BBB opening, a therapeutic agent is administered systemically e.g., within about 15 to about 120 minutes post-sonication). In some implementations, the therapeutic agent is administered within about 15 to about 45 minutes post-sonication. In some implementations, the therapeutic agent is administered intravenously within about 15 to about 30 minutes post-BBB opening. The therapeutic agents deliverable via this platform include any of the therapeutic agent classes described herein, including without limitation anti-amyloid antibodies, anti-tau antibodies, small-molecule CNS therapeutics, viral gene therapy vectors, non-viral nucleic acid delivery constructs, CRISPR-Cas9 gene editing constructs, and cellbased therapeutic constructs.
[0168] In some implementations, post-procedure steps include: withdrawal of the catheter body 100 under fluoroscopic guidance, application of IJV compression for about 10 minutes, gadolinium-enhanced MRI within about 60 minutes to confirm BBB opening, T2 / FLAIR monitoring, and / or patient observation for about 4 hours.
[0169] In some implementations, in an Alzheimer’s disease treatment protocol, lecanemab or equivalent anti-amyloid protofibril antibody is administered intravenously within about 30 minutes of completion of the BBB opening sonication sequence. Treatment may be performed monthly or bimonthly with magnetic resonance imaging (MRI) monitoring per standard anti-amyloid immunotherapy protocols.
[0170] In some implementations, heparinized saline irrigation at a controlled flow rate of about 1 mL / min is delivered via dedicated lumens in the catheter shaft. This irrigation may serve dual purposes: thermal management of the one or more transducer elements 102CHZ-00225and prevention of thrombosis during prolonged catheter dwell time within the low-flow venous sinus environment.
[0171] An expandable scaffold may be deployed proximal to the transducer to maintain catheter position within the venous lumen, center the emitter, and prevent direct vessel wall contact. In the straight sinus configuration, the scaffold can be adapted to the triangular cross-sectional geometry of the sinus.
[0172] In some implementations, the catheter system is configurable for the following therapeutic modalities by adjustment of operating parameters: (a) BBB modulation for drug delivery — low-intensity pulsed FUS with microbubbles, MI about 0.2 to about 0.6; (b) neuromodulation — low-intensity pulsed ultrasound without microbubbles, ISPTA less than about 100 mW / cm2; (c) sonodynamic therapy — pulsed FUS with systemically administered sonosensitizer agents; (d) thermal neuroablation — HIFU with continuous or high-duty -cycle waveforms; (e) intravascular imaging — high-frequency (about 20 to about 50 MHz) pulseecho imaging; and (f) sonothrombolysis — moderate-intensity pulsed FUS for cerebral venous sinus thrombosis.
[0173] The disclosed subject matter contemplates delivery of the following therapeutic agent classes following BBB modulation, without limitation: (a) monoclonal antibodies targeting amyloid-beta, tau, alpha-synuclein, TDP-43, or other central nervous system (CNS) pathological protein aggregates; (b) enzyme replacement therapies for lysosomal storage disorders with CNS involvement; (c) recombinant viral gene therapy vectors including adeno-associated vims (AAV) serotypes AAV1, AAV2, AAV5, AAV9, AAVrhlO, and other serotypes, carrying therapeutic transgenes; (d) non-viral nucleic acid delivery constructs including lipid nanoparticles, polymer nanoparticles, or exosome-based vehicles carrying messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides (ASOs), or clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 components; (e) small-molecule CNS drugs with limited BBB penetrance under physiological conditions; (f) cell-based constructs including stem cell-derived neural progenitors, chimeric antigen receptor T (CAR-T) cells, or regulatory immune cells; and (g) diagnostic imaging agents.
[0174] In some implementations, the catheter system is applicable to treatment of neurological conditions beyond Alzheimer’s disease, including without limitation:Parkinson’s disease, in which the therapeutic agent targets alpha-synuclein aggregates, GBA enzyme deficiency, or URRK2 / SNCA gene variants; amyotrophic lateral sclerosis (AUS), in which the therapeutic agent targets SOD1, TDP-43, or FUS protein aggregates;CHZ-00225frontotemporal dementia (FTD), in which the therapeutic agent targets TDP-43, C9orf72, or progranulin deficiency; Huntington’s disease, in which the therapeutic agent includes HTT-silencing siRNA, antisense oligonucleotides, or CRISPR-Cas9 constructs; multiple sclerosis, in which the therapeutic agent includes remyelination agents, anti-inflammatory biologies, or neuroprotective lipid nanoparticle constructs; spinal muscular atrophy, in which the therapeutic agent includes SMN1 gene therapy via AAV9 vectors; lysosomal storage disorders with CNS involvement, including Gaucher’s disease (GBA), Canavan disease (ASPA), neuronal ceroid lipofuscinoses (CLN2, CLN3, CLN6), and Sanfilippo syndrome type B (NAGLU); glioblastoma and CNS metastatic disease, in which the therapeutic agent includes sonodynamic therapy with sonosensitizer agents, chimeric antigen receptor T (CAR-T) cells, oncolytic viral vectors, or immune checkpoint agents delivered following BBB modulation; epilepsy, in which thermal neuroablation of focal cortical seizure foci or GAD1 AAV-mediated GABAergic modulation is performed; and traumatic brain injury, in which neuroprotective agents or anti-inflammatory biologies are delivered via enhanced BBB permeability.
[0175] In some implementations, the therapeutic transgene carried by an AAV vector is selected from the group consisting of: GBA for Parkinson’s disease or Gaucher’s disease with CNS involvement; SMN1 for spinal muscular atrophy; an HTT-silencing construct for Huntington’s disease; ASPA for Canavan disease; CLN2, CLN3, or CLN6 for neuronal ceroid lipofuscinoses (Batten disease); LRRK2 or SNCA for Parkinson’s disease; SOD1-targeting constructs for amyotrophic lateral sclerosis; progranulin (GRN) for frontotemporal dementia; and NAGLU for Sanfilippo syndrome type B. Each transgene may be packaged in an AAV serotype selected for optimal transduction of the target cell population, including but not limited to AAV9 for broad neuronal transduction, AAV5 for cortical neurons, and AAVrhlO for both neuronal and glial cells.
[0176] In some implementations, the therapeutic transgene encodes an enzyme whose deficiency causes a CNS -manifesting enzyme deficiency disorder, including but not limited to lysosomal storage disorders with neurological involvement. In some implementations, the therapeutic transgene comprises an inhibitory nucleic acid construct targeting a gene product associated with pathological protein aggregation in a neurodegenerative disease.
[0177] In some implementations, cell-based therapeutic constructs deliverable via BBB modulation include: chimeric antigen receptor T cells (CAR-T) engineered to target a CNS tumor antigen for treatment of glioblastoma or CNS lymphoma; neural stem cell-derived progenitors for neurodegenerative disease including Parkinson’s disease and ALS;CHZ-00225regulatory T cells for neuroinflammatory conditions including multiple sclerosis; and induced pluripotent stem cell (iPSC)-derived dopaminergic neurons for Parkinson’s disease. Cellbased therapies may be administered systemically following BBB modulation to enhance CNS engraftment and biodistribution at the target site.
[0178] In some implementations, the therapeutic agent is a recombinant enzyme selected for replacement therapy in a lysosomal storage disorder with CNS involvement. Such enzymes may include, without limitation: glucocerebrosidase for Gaucher’s disease; iduronate-2-sulfatase for Hunter syndrome; alpha-L-iduronidase for Hurler syndrome; N-acetylglucosaminidase for Sanfilippo syndrome type B; and other recombinant enzymes for CNS -manifesting lysosomal storage disorders. Enzyme replacement therapy agents administered systemically following BBB modulation may achieve enhanced CNS parenchymal concentrations relative to administration without prior ultrasound-mediated BBB opening.
[0179] Referring now to FIG. 8, a coronal cross-sectional view at the L1-L2 vertebral level is shown, depicting the catheter body 100 deployed in the inferior vena cava (IVC) 802 in an IVC configuration. Although described with reference to hepatic and pancreatic targets, the dual-frequency IVC configuration is broadly applicable to ablation of any solid tumor accessible from a major venous conduit, including without limitation renal, adrenal, and retroperitoneal tumors. In some implementations, a therapeutic beam (HIFU) 804 at about 1.5 MHz and an imaging beam 806 at about 10 MHz B-mode are directed toward a hepatic tumor 808 and a pancreatic tumor 810, with the liver 812 and pancreas 814 shown for anatomical context. The IVC configuration may represent a different implementation of the catheter body 100 architecture, utilizing dual-frequency operation including about 1.5 MHz high-intensity focused ultrasound (HIFU) for therapeutic energy delivery and about 10 MHz imaging for real-time B-mode anatomical visualization. In some implementations, the transducer array 122 in the IVC configuration includes a HIFU element 1122 and an imaging element 1124, enabling simultaneous or interleaved treatment delivery and real-time visualization from a single integrated catheter platform.
[0180] Referring now to FIG. 9, transverse cross-sectional views at the shaft section (about 12 Fr, approximately 4.0 mm outer diameter) and transducer zone (about 14 Fr, approximately 4.7 mm outer diameter) of the catheter body 100 in the IVC configuration are shown, depicting the lumen layout including guidewire lumen, irrigation lumen, coaxial signal cables, and transducer elements 102, with reference numerals: IVC lumen 802,CHZ-00225catheter body 100 (e.g., PEBAX 72D), and transducer array 122 (e.g., PMN-PT, about 8 elements).
[0181] Referring now to FIG. 10, a longitudinal section of a catheter system is shown, depicting the catheter body 100 having a total length of about 1100 mm. At the proximal end, a hub / connector 1010 provides a mechanical and electrical interface for coupling the catheter body 100 to external drive electronics, signal processing equipment, and ancillary systems. A torque-rotation marker 1050 is provided along the shaft for rotational position indication. A passive cavitation detection (PCD) element 1030 is positioned along the catheter body 100 for receiving acoustic emissions from the treatment zone. At the distal working end, the dualfrequency transducer array 122 occupies a transducer zone of about 35 mm in length and is configured for both therapeutic sonication and real-time imaging. Distal to the transducer array 122, a flexible atraumatic tip 1040 is provided, comprising, e.g., PEBAX 35D material, which is a polyether block amide (PEBA) thermoplastic elastomer having a Shore D hardness of approximately 35. It should be noted that the catheter body 100 in the IVC configuration represents a different implementation or application of the same catheter body 100 architecture described herein, rather than a separate or distinct catheter device.
[0182] In some implementations, a dual-mode intravascular catheter system is provided and includes a phased array of piezoelectric transducer elements operable in a first imaging mode and a second therapeutic mode. In some implementations, the phased array of piezoelectric transducer elements are operable in the first imaging mode at about 5 to about 15 MHz for real-time B-mode ultrasound visualization (e.g., visualization of hepatic and pancreatic tumor targets). In some implementations, the phased array of piezoelectric transducer elements are operable second therapeutic mode at about 1 to about 3 MHz for high-intensity focused ultrasound (HIFU) ablation of said targets. The catheter may be configured for percutaneous deployment within the inferior vena cava (IVC) or hepatic veins e.g., as shown in FIG. 8). In some implementations, a closed-loop thermal dosimetry system monitors acoustic emissions and estimated tissue temperature in real time, enabling controlled coagulative necrosis of tumor tissue while preserving adjacent vascular structures.
[0183] Referring to FIGS. 8-10, in some implementations, the catheter body 100 in the IVC configuration includes an outer sheath fabricated from, e.g., PEBAX 72D with an outer diameter of about 4.0 to about 5.0 mm (about 12 to about 15 Fr) and a working length of about 1100 mm, suitable for femoral venous access and advancement to the intrahepatic IVC. A proximal about 700 mm rigid-flex shaft may transition to about a 400 mm steerable distal segment with about a 60 mm deflectable tip 1040 fabricated from, e.g., PEBAX 35D.CHZ-00225In some implementations, a stainless steel 304 flat-wire braid reinforcement provides pushability and torque transmission. The lumen stack may include: a 0.035” central guidewire lumen; dual coaxial signal cables (about 50 ohm, about 8 channels each for HIFU and imaging arrays); about a 1.2 mm irrigation lumen delivering active coolant; and a dedicated about 0.4 mm thermocouple lumen for proximal IVC wall temperature monitoring.
[0184] The transducer array 122 may occupy about a 35 mm axial zone on the catheter distal segment (e.g., as shown in FIG. 11). In some implementations, the transducer array 122 has a total axial footprint of about 40 mm or less and an outer diameter of about 5 mm or less. In some implementations, the transducer array 122 includes two interleaved linear arrays oriented circumferentially: a therapeutic array of at least about 8 PMN-PT single-crystal transducer elements 102 (piezoelectric constant dii of at least about 1200 pC / N, and in some implementations greater than about 1400 pC / N) resonant at about 1.5 MHz, each of the one or more transducer elements 102 having dimensions of about 4 mm (azimuth) x about 2 mm (elevation), with a pitch in the range of about 0.4 mm to about 0.7 mm, and in some implementations about 0.5 mm; and an imaging array of at least about 16 PMN-PT transducer elements 102 resonant at about 10 MHz, each of the one or more transducer elements 102 having dimensions of about 2 mm x about 1.5 mm, with a pitch in the range of about 0.2 mm to about 0.3 mm, and in some implementations about 0.25 mm. In some implementations, the therapeutic transducer elements are stacked below the imaging transducer elements with about a 50 pm epoxy isolation layer 1164 between arrays (e.g., as shown in FIG. 11). In some implementations, electronic steering of the therapeutic and imaging beams is performed in the azimuthal dimension over a range of about ±45° from the catheter longitudinal axis.
[0185] Two broadband PCD elements 1030, fabricated from, e.g., polyvinylidene fluoride (PVDF) film (about 28 pm), are co-located on the catheter body 100 approximately 5 mm proximal and distal to the first set of piezoelectric elements (therapeutic array) (e.g., as shown in FIG. 10). In some implementations, the PCD elements 1030 are disposed within about 10 mm of the transducer array. The PCD elements 1030 receive acoustic emissions in the frequency range of about 0.2 to about 5 MHz. In-band analysis detects sub-harmonic emission at fo / 2 e.g., about 750 kHz for about 1.5 MHz operation), indicative of stable cavitation. Broadband noise floor elevation indicates inertial cavitation. In some implementations, a hardware interlock reduces therapeutic power by at least about 30% within about 2 ms of inertial cavitation detection. In some implementations, the hardware interlock reduces therapeutic power by about 40% within about 1 ms of inertial cavitationCHZ-00225detection. PCD element 1030 output is also used to estimate the spatial extent of microbubble activity and as a surrogate for acoustic energy deposition at the focal zone.
[0186] Referring now to FIG. 11, an exploded cross-sectional view of a dualfrequency transducer stack architecture in which a therapeutic low-frequency transducer element and a diagnostic high-frequency transducer element are co-located in a layered configuration within a catheter-scale form factor is shown. Although described with reference to specific materials and dimensions for the IVC configuration, the dual-frequency transducer stack architecture illustrated in FIG. 11 is broadly applicable to any catheter implementation described herein requiring both diagnostic imaging and therapeutic energy delivery. The transducer stack may include, from an outermost position to an innermost position: an acoustic lens 1160 configured to provide mechanical beam focusing and impedance matching; a matching layer 1162 configured for acoustic coupling between the transducer elements and a surrounding medium; a HIFU element 1122 configured for therapeutic acoustic energy delivery at a first frequency; an isolation layer 1164 configured to provide acoustic and electrical isolation between the HIFU element 1122 and an imaging element 1124; the imaging element 1124 configured for diagnostic imaging at a second frequency higher than the first frequency; a ground electrode 1166 providing a common electrical reference; a backing 1168 configured to attenuate rearward-propagating acoustic energy; and PCB signal routing 1170 configured for independent electrical connection to each transducer element. The specific materials, layer thicknesses, operating frequencies, active element dimensions, and number of channels may be varied to suit different clinical applications, target tissue depths, vascular deployment sites, and catheter form factors, as described herein. In some implementations, the therapeutic frequency is between about 500 kHz and about 5 MHz, and the diagnostic frequency is between about 5 MHz and about 50 MHz. In some implementations, the transducer stack is configured for integration into a catheter body 100 having an outer diameter between 3 Fr and 15 Fr.
[0187] In some implementations, the acoustic lens 1160 includes silicone roomtemperature-vulcanizing (RTV) material with a focal number f of about 30 and a quarterwavelength (X / 4) thickness design, providing impedance matching and mechanical focusing of the acoustic beam. In some implementations, the acoustic lens 1160 has a radius of curvature of about 30 mm. In some implementations, the acoustic lens 1160 has a fixed geometric focal length in the range of about 20 mm to about 40 mm in the elevation dimension, and in some implementations a default geometric focus at about 25 mm to about 35 mm from the catheter axis. In some implementations, the matching layer 1162 includesCHZ-00225parylene-C (e.g., at a thickness of about 120 microns), providing acoustic impedance matching between the transducer elements and the surrounding medium. In some implementations, the HIFU element 1122 includes PMN-PT single crystal material operating at a center frequency of about 1.5 MHz, with an active area of about 4 mm by about 2 mm. In some implementations, the isolation layer 1164 includes epoxy at a thickness of about 50 microns, positioned between the HIFU element 1122 and the imaging element 1124, providing both acoustic and electrical isolation to minimize cross-talk. In some implementations, the imaging element 1124 includes PMN-PT single crystal material operating at a center frequency of about 10 MHz, with an active area of about 2 mm by about 2 mm. In some implementations, the ground electrode 1166 includes copper (Cu) foil, providing a common electrical ground reference for both the HIFU element 1122 and the imaging element 1124. In some implementations, the backing 1168 includes tungsten-loaded epoxy (W-epoxy) and provides at least about -35 dB, and in some implementations about -40 dB, of acoustic attenuation for rearward-propagating acoustic energy. In some implementations, the PCB signal routing 1170 is provided in an 8-channel configuration with 50 ohm microcoaxial cables.
[0188] Referring now to FIG. 12, a system block diagram showing the complete electronic system architecture of an inferior vena cava intravascular focused ultrasound (IVC-IFUS) configuration is depicted, including: catheter body 100, dual-frequency beamformer 1210, image processor 1220, HIFU power amplifier 1230, thermal dosimetry module 1240, motion compensation module 1250, treatment planner 1260, and display / control interface 1270. Although described with reference to the IVC-IFUS configuration, the electronic system architecture illustrated in FIG. 12 is broadly applicable, with appropriate parameter adjustment, to any catheter implementation described herein.
[0189] In some implementations, the dual-frequency beamformer 1210 generates and receives both HIFU signals at about 1.5 MHz and imaging signals at about 10 MHz, and controls electronic beam steering and focusing of the transducer array 122 by applying appropriate phase delays and amplitude weights to the individual transducer element 102 channels. The image processor 1220 receives B-mode imaging data from the imaging element 1124 via the dual-frequency beamformer 1210 and processes the received data for real-time display. The HIFU power amplifier 1230 may receive therapeutic waveforms from the dual-frequency beamformer 1210 and may amplify those waveforms to drive the HIFU element 1122 at therapeutic power levels. The thermal dosimetry module 1240 may monitor and calculate the thermal dose delivered to the target tissue during treatment, and mayCHZ-00225integrate with imaging data to generate thermal maps. The motion compensation module 1250 may compensate for patient respiratory motion and cardiac motion during treatment, which may be particularly important for IVC-based abdominal treatments where the liver 812, pancreas 814, and associated tumors 808, 810 may be subject to periodic displacement due to the respiratory cycle. In some implementations, the motion compensation module 1250 employs tracking algorithms based on imaging data from the imaging element 1124 to estimate tissue displacement in real time and adjust the beamforming parameters of the dualfrequency beamformer 1210 accordingly. The treatment planner 1260 may provide pretreatment planning functionality, including target definition, dose prescription, and treatment sequence configuration. The display / control interface 1270 may provide the operator-facing user interface, including real-time imaging display, treatment parameter readouts, cavitation monitoring feedback from the PCD element 1030, and system controls for initiating, pausing, adjusting, and terminating treatment.
[0190] In some implementations, tissue temperature in the IVC configuration is estimated using two complementary methods e.g., as shown in FIG. 12). First, backscattered ultrasound spectral shift at the imaging frequency (about 10 MHz) may provide a non-invasive temperature estimate based on the speed-of-sound temperature coefficient e.g., about +0.24 m / s per degree C in hepatic tissue, about 37 to about 60 degrees C range).Second, about a 0.2 mm thermocouple embedded in the catheter wall may provide continuous measurement of IVC wall temperature, serving as a safety interlock (abort threshold about 43 degrees C). Cumulative equivalent minutes at 43 degrees C (CEM43) may be integrated in real time; a target dose of CEM43 = about 240 (equivalent to standard HIFU ablation threshold) may trigger automatic termination of sonication at each focal zone.
[0191] In some implementations, respiratory -induced hepatic motion of about 10 to about 35 mm (craniocaudal) and cardiac pulsatility of about 2 to about 5 mm at the IVC wall are addressed through the motion compensation module 1250. In some implementations, speckle tracking on sequential B-mode frames (frame rate of about 20 Hz or greater) estimates 2D tissue displacement vectors at the focal zone. The dual-frequency beamformer 1210 may apply computed phase corrections on a pulse-by-pulse basis to maintain focal zone registration within about + / - 1 mm. For residual motion exceeding about + / - 3 mm, therapeutic pulsing may be gated to expiratory breath-hold periods using respiratory monitoring via, e.g., a peripheral SpCh waveform input or direct acoustic signal variance.
[0192] In some implementations, under conscious sedation, femoral venous access is obtained and, e.g., about a 16 Fr introducer sheath placed. The catheter body 100 may beCHZ-00225advanced over a 0.035” guidewire under fluoroscopic guidance to the intrahepatic IVC segment at the level of the target tumor (e.g., L1-T8 vertebral level for hepatic targets; L1-L2 for pancreatic head / body targets). Heparinization e.g., ACT about 200 to about 250 s) may be maintained throughout. Irrigation saline e.g., at a flow rate of about 20 to about 50 mL / min, and in some implementations about 30 mL / min, at about 20 degrees C) may be initiated. The imaging mode may be activated and the target tumor identified on B-mode using the imaging element 1124 operating at about 10 MHz. Tumor boundaries may be defined and focal ablation zones programmed on the treatment planner 1260. The HIFU mode may be activated via the HIFU element 1122 and each zone ablated sequentially, with real-time thermal dosimetry confirmation via the thermal dosimetry module 1240. In some implementations, total procedure time is estimated at about 60 to about 120 minutes for tumors of about 5 cm diameter or less.
[0193] In some implementations, in addition to hepatic and pancreatic targets, the catheter body 100 in the IVC configuration may be further configured for ablation of renal cell carcinoma (RCC) and renal metastases. The inferior vena cava lies in direct anatomical adjacency to the kidneys, with renal veins draining directly into the IVC at the L1-L2 vertebral level. The catheter body 100 may be positioned within the IVC at the level of the renal hilum, or advanced into a renal vein, to achieve focused ultrasound ablation of renal parenchymal tumors at depths of about 10 to about 80 mm from the catheter axis. Renal tumors located in the medial cortex, renal hilum, or adjacent to the collecting system — which may be inaccessible or high-risk for conventional percutaneous ablation — may be addressable via the intravascular approach. The dual -frequency transducer array 122 may provide realtime B-mode imaging for tumor localization and boundary delineation within the renal parenchyma, followed by therapeutic HIFU ablation with closed-loop thermal dosimetry as described for hepatic targets. Motion compensation via respiratory gating and speckle tracking may be similarly applicable to renal targets subject to respiratory excursion.
[0194] In a further implementation, a coordinated two-catheter intracranial treatment system is provided in which a first catheter may be deployed within the superior sagittal sinus (SSS) and a second catheter may be deployed within the straight sinus, either sequentially or simultaneously during a single interventional procedure. In some implementations, the SSS catheter is a higher-caliber device optimized for the about 6.0 to about 9.9 mm lumen diameter of the SSS, configured for broad radial or circumferential acoustic energy delivery to medial cortical structures including the PCC, precuneus, ACC, medial prefrontal cortex, paracentral lobule, and superior parietal lobule. In some implementations, the straight sinusCHZ-00225catheter is a smaller-caliber device with a tip profile of about 3.0 to about 3.5 mm OD, optimized for the about 4 to about 6 mm triangular lumen of the straight sinus, configured for focused acoustic energy delivery to the hippocampal-entorhinal circuit via a multi-element curved phased array (e.g., as shown in FIG. 3).
[0195] In the coordinated configuration, the catheter system (for the SSS configuration) may provide broad-field BBB modulation or neuromodulation across the default mode network and medial cortical surfaces, while the straight sinus catheter may provide targeted, focused BBB opening at hippocampal, entorhinal, and amygdalar structures. This complementary coverage may enable treatment of both superficial cortical amyloid burden (via SSS) and deep medial temporal tau and amyloid pathology (via straight sinus) in a single procedural session. Following coordinated BBB opening across both vascular corridors, any of the therapeutic agent classes described herein may be administered systemically within about 15 to about 120 minutes post-sonication, and in some implementations within about 15 to about 45 minutes post-sonication, to achieve enhanced CNS biodistribution across the full Alzheimer’s disease-relevant anatomical network.
[0196] The two-catheter configuration may alternatively be used in non-BBB modalities. For example, the SSS catheter may be operated in neuromodulation mode targeting default mode network hubs while the straight sinus catheter may be operated in focused BBB opening mode at hippocampal targets, or both catheters may be operated in thermal ablation mode to address spatially distributed cortical or subcortical lesions accessible from their respective vascular corridors. Both catheters may be navigated via the same jugular venous access route, right internal jugular vein to sigmoid sinus to transverse sinus, with the SSS catheter advanced superiorly along the midline and the straight sinus catheter advanced via the torcular Herophili into the sinus rectus e.g., as shown in FIG. 4). Catheter positions may be confirmed independently by fluoroscopy using distinct radiopaque marker patterns, and MRI co-registration may enable coordinated pre-procedure treatment planning for both devices.
[0197] The acoustic window of any catheter implementation described herein may be configured to enable at least 180-degree radial emission and may include angular emission control. Angular emission control refers to the ability to selectively direct or restrict acoustic energy output to a defined angular sector of the radial emission field, for example by segmented activation of transducer sub-elements, by mechanical rotation of a directional emitter, or by incorporation of an asymmetric acoustic reflector or absorber within the catheter body. This feature enables preferential targeting of specific tissue regions e.g.,CHZ-00225ipsilateral cortex) while minimizing exposure to non-target anatomy on the opposite side of the vessel lumen.
[0198] The closed-loop control system of any catheter implementation described herein may further include a proximity sensor configured to detect the distance between the transducer and the vessel wall or adjacent tissue surface. The proximity sensor may operate via ultrasonic pulse-echo ranging, optical time-of-flight measurement, or impedance -based tissue detection. Proximity data is fed to the feedback controller, which adjusts energy delivery parameters — including output power, pulse duration, and duty cycle — based on the detected distance to maintain therapeutic efficacy while preventing vessel wall injury. In combination with the temperature sensor described in the intracranial and IVC implementations, the proximity sensor enables multi-parameter closed-loop control of acoustic energy delivery.
[0199] Any catheter implementation described herein may further include a positional sensing system for real-time emitter localization. Positional sensing may be achieved via electromagnetic tracking coils embedded in the catheter tip, impedance-based intracardiac or intravascular navigation, integration with external optical or magnetic tracking systems, or co-registration with fluoroscopic or MRI positional data. Real-time emitter localization enables precise treatment planning, dynamic adjustment of sonication zones during a procedure, and post-procedure confirmation of treated volumes.
[0200] Any catheter implementation described herein may further be configured to monitor intravascular structures during or prior to therapeutic energy delivery. The system may comprise a signal processing unit for detecting and characterizing the presence of indwelling medical devices (e.g., stents, coils, or ventriculoperitoneal shunt tubing), thrombi, calcifications, or foreign bodies within the vessel lumen based on acoustic backscatter signatures, Doppler shift analysis, or B-mode imaging pattern recognition. This monitoring capability is operable in real-time and co-registered with energy delivery pathways, enabling the control system to adjust or halt sonication if an obstruction or hazard is detected in the beam path.
[0201] In any method implementation described herein, the step of modulating energy delivery may include real-time distance monitoring via the proximity sensor, adaptive energy output based on proximity to the vessel wall and tissue compliance, and frequency adjustment based on feedback from temperature, cavitation, or proximity sensors. These adaptive modulation features enable the system to maintain therapeutic efficacy across varying anatomical geometries and tissue conditions without manual operator intervention.CHZ-00225
[0202] In any method implementation described herein, the system may further measure blood flow velocity or pulsatility using Doppler ultrasonography from the imaging transducer elements, modify treatment parameters based on detected flow dynamics (e.g., reducing power during high-flow states to prevent thermal washout, or gating sonication to low-flow phases), and log treatment data including flow measurements, power settings, cavitation spectra, and thermal dose via fiberoptic telemetry extending through the catheter shaft. The fiberoptic telemetry pathway may transmit data optically to reduce electromagnetic interference and enable MR-compatible data acquisition.
[0203] In any method implementation described herein, the acoustic emission may be pulsed with a variable duty cycle ranging from 0.1% to 50%, and active cooling via heparinized saline irrigation may be applied between pulses to manage transducer and vessel wall thermal load. The duty cycle and inter-pulse cooling rate may be adjusted dynamically based on real-time temperature feedback from the thermocouple or acoustic thermometry subsystem.
[0204] In any method implementation described herein, a sensitizing agent or microbubble contrast agent may be administered systemically during or prior to acoustic emission to enhance therapeutic effect. In the BBB modulation context, microbubbles facilitate stable cavitation and transient BBB opening. In the thermal ablation context, microbubbles may enhance acoustic energy deposition at the focal zone, reducing the acoustic power threshold required for coagulative necrosis. Sensitizing agents, including sonosensitizers for sonodynamic therapy, may be administered in conjunction with acoustic emission to achieve targeted cytotoxicity in tumor tissue.
[0205] The catheter systems and methods described herein are informed by a quantitative analytical framework characterizing acoustic propagation, energy attenuation, and thermal deposition within layered intracranial and perivascular tissue. This framework establishes the operating parameters, including frequency range, emission geometry, aperture dimensions, and thermal dose constraints, that may govern the architecture of the various catheter implementations. The specific numerical values and tissue parameters presented herein are representative and not limiting; one may adapt these parameters to accommodate different anatomical targets, vascular conduits, or clinical indications without departing from the scope of the disclosed subject matter.
[0206] A cylindrical ultrasound emitter (1-2 mm aperture) was modeled as a high-intensity, unfocused source operating at 2.0 MHz. Acoustic propagation was simulated radially through five contiguous tissue layers (blood, vein wall, dura mater, CSF, and cerebralCHZ-00225cortex) using exponential attenuation and adiabatic thermal conversion. The initial pressure was 1.0 MPa, with insonation time held at 0.5 s. No electronic beam steering, focusing, or phased excitation was modeled; the emitter was treated as a single-phase, non-steered radial source consistent with capacitive micromachined ultrasound transducer (CMUT) or piezoelectric micromachined ultrasound transducer (PMUT) architectures integrated into 5-6 Fr catheter platforms. CMUT devices operate via electrostatic actuation of a DC-biased membrane modulated by AC drive, while PMUT devices utilize piezoelectric strain in thin-film diaphragms. Both architectures support catheter-scale form factors and MHz-range operation, with demonstrated peak output pressures exceeding 1 MPa under burst-mode excitation. The acoustic window was approximated as a -100 pm Pebax membrane with estimated attenuation under 0.2 dB at 2 MHz (<5% power loss), treated as negligible.Diffraction, nonlinear effects, conduction, and perfusion were excluded to conservatively estimate core feasibility. Under these conditions, temperature elevation exceeded 1.5 °C at cortical depths of 3-5 mm from the vessel wall within 0.5 seconds of insonation. Cumulative transmission loss across the full tissue stack was under 2 dB. The reflection coefficient at the blood-vessel wall interface was calculated at R ~ 8.5 x 105, indicating that less than 0.01% of incident acoustic energy is reflected. These results confirm that efficient acoustic energy transfer may be achieved through unfocused radial emission without beamforming or geometric focusing, provided anatomical proximity to the vascular conduit is maintained.
[0207] The superior sagittal sinus (SSS) was used as the reference conduit for modeling due to its midline caliber (6.0-9.9 mm in adults), consistent geometry, and established clinical precedent for catheter deployment. However, the modeling framework may generalize to any large-caliber intracranial venous segment meeting comparable geometric and acoustic criteria. The unfocused radial configuration may be optimized for cortical and near-cortical targets located within 1-5 mm of the vessel wall, including parasagittal regions such as the sensorimotor and parietal cortices. Deeper or laterally displaced targets may fall outside the propagation domain of the unfocused radial configuration and may benefit from modified emission strategies such as focusing geometries, steerable arrays, or reduced-frequency operation.
[0208] Beyond the SSS, several candidate intracranial venous structures may offer anatomical proximity to eloquent cortex and may be suitable for catheter-based ultrasound energy delivery. These may include the vein of Trolard (2.1-3.3 mm, adjacent to somatosensory cortex and posterior parietal lobe), the Rolandic vein (up to 4.9 mm, adjacent to the pre- and postcentral gyms sensorimotor strip), the anterior parietal vein (approximatelyCHZ-002252.2 mm, adjacent to superior parietal cortex), the vein of Galen (4-6 mm, adjacent to the pineal region and midbrain), the straight sinus (3-5 mm, adjacent to thalamus and pineal body), the basal vein of Rosenthal (2-3 mm, adjacent to mesial temporal lobe and hippocampus), and the transverse sinus (6-9 mm, with indirect access to posterior parietal cortex via the torcula). Access to smaller-caliber tributaries may require steerable microcatheters or guidewire-assisted navigation. Arterial routes, such as the cavernous internal carotid artery may provide proximity to orbitofrontal and insular cortex, although high flow velocities, thick muscular walls, and increased thermal sensitivity may make such routes less favorable for stable emitter deployment compared to venous pathways.
[0209] The disclosed catheter system architecture may be deployed in any blood vessel of sufficient caliber to accommodate the catheter, including but not limited to intracranial arteries, dural venous sinuses, the inferior vena cava, hepatic veins, renal veins, and other major venous or arterial conduits, with appropriate adjustment of tissue layer thicknesses, attenuation coefficients, and operating parameters for the target anatomy. This approach may eliminate skull-related losses, geometric access constraints, and alignment complexities inherent to extracranial systems, and may enable scalable, repeatable energy deposition to targets otherwise inaccessible due to skull impedance or acoustic window geometry.
[0210] In practice, intraluminal cooling or burst-mode operation may be employed to manage tip heating. Burst-mode excitation, in which acoustic energy is delivered in short pulses with inter-pulse cooling intervals, may enable higher peak pressures while maintaining acceptable thermal loads at the transducer and vessel wall. The duty cycle and burst duration may be adjusted based on real-time temperature feedback. The modeled emitter geometry is consistent with catheter-scale device constraints of 3-6 Fr.
[0211] The disclosed catheter system architecture accommodates several system-level design tradeoffs. Aperture size (total active emitting surface area of the transducer element or array) is balanced against catheter flexibility; larger emitters provide greater directional control, while smaller emitters preserve trackability through tortuous intracranial anatomy. Operating frequency is selected to balance spatial resolution against tissue penetration depth for each target application. Catheter integration accommodates internal conductors, electromagnetic shielding, and acoustic isolation within the device profile constraints of 3-6 Fr catheter bodies. The disclosed implementations further address emitter complexity through microfabricated wiring and multiplexing architectures compatible with sub-2 mm catheter shafts; transducer and tip thermal management through active irrigation and duty-cycleCHZ-00225control; acoustic impedance matching at the blood-tissue interface through quarterwavelength matching layers and lens geometries; catheter positional stability through expandable scaffolding and positional sensing; MR compatibility through selection of nonferromagnetic materials and fiberoptic signal pathways; and directional acoustic access through angular emission control and electronic beam steering.
[0212] It is to be understood that features, elements, components, parameters, operating modes, materials, numerical ranges, and methods disclosed in connection with any particular implementation described herein may be combined with or incorporated into any other implementation described herein, unless expressly stated otherwise or structurally incompatible. For example, materials, transducer configurations, control algorithms, operating parameters, drug delivery protocols, and monitoring subsystems described with reference to one catheter configuration or anatomical target may be applied to any other catheter configuration or anatomical target disclosed herein. The implementations are presented individually for clarity of description, and the scope of the disclosed subject matter encompasses all permutations and sub-combinations of the disclosed features.
[0213] The descriptions of the various implementations of the present disclosure have been presented for purposes of illustration, but are not intended to be exhaustive or limited to the implementations disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described implementations. While some examples presented herein involve specific combinations of functions or structural elements, it should be understood that those functions and elements may be combined in other ways according to the present disclosure to accomplish the same or different objectives. Elements, components, and features discussed in connection with one implementation are not intended to be excluded from other implementations. Additionally, elements, components, and features described herein may be further divided into additional components or joined together to form fewer components for performing the same or similar functions. The terminology used herein was chosen to best explain the principles of the implementations, the practical application or technical improvement over technologies found in the marketplace, or to enable others of ordinary skill in the art to understand the implementations disclosed herein.
Claims
CHZ-00225CLAIMS1. A therapeutic and diagnostic ultrasound system for intracranial vascular applications, comprising:an elongated flexible catheter body configured for navigation through intracranial arteries or dural venous sinuses including the superior sagittal sinus, straight sinus, transverse sinus, sigmoid sinus, inferior sagittal sinus, basal vein of Rosenthal, or vein of Galen;at least one ultrasound transducer element integrated within or at a distal portion of said catheter body; an acoustic window formed in a wall of the catheter body or at a tip of the catheter body, composed of a low-acoustic-attenuation material; anda control system operatively connected to said at least one ultrasound transducer element;wherein said at least one ultrasound transducer element is configured to emit acoustic energy in at least one emission mode selected from: radially outward from the catheter body, circumferentially around the catheter body, focused to a defined tissue depth, or axially forward from the tip of the catheter body; and wherein the system operates without requiring transcranial beam steering or extracranial phased-array control.
2. A method for blood-brain barrier modulation comprising:positioning a catheter within a dural venous sinus of a subject; administering a microbubble contrast agent systemically;delivering pulsed focused ultrasound energy through said catheter at a mechanical index between 0.1 and 0.7 and a spatial-peak temporal-average intensity (ISPTA) of 720 mW / cm2 or less; andadministering a therapeutic agent systemically within 15 to 120 minutes following delivery of said pulsed focused ultrasound energy;wherein the therapeutic agent achieves enhanced brain tissue concentration relative to administration without prior ultrasound treatment.
3. An intravascular focused ultrasound catheter system configured for deployment within the straight sinus, comprising:an elongated catheter body with an outer diameter of 4.5 mm or less;CHZ-00225a transducer array configured to conform to an internal geometry of the straight sinus and to electronically steer an acoustic focus to depths of 10 to 60 mm from a lumen of the straight sinus;at least two passive cavitation detection elements co-located on the catheter body adjacent to the transducer array; a closed-loop control system configured to distinguish stable cavitation from inertial cavitation based on detected acoustic spectra and to adjust output power accordingly; andat least one irrigation lumen for delivery of heparinized saline.
4. A method for delivering a therapeutic agent to hippocampal or entorhinal cortex tissue in a subject with a neurological condition, comprising:advancing an ultrasound catheter through the venous system to the straight sinus via an access route;delivering pulsed ultrasound energy from said catheter in combination with systemically administered microbubbles to transiently increase blood-brain barrier permeability in tissue anatomically adjacent to the straight sinus; andadministering said therapeutic agent systemically within a defined time window following blood-brain barrier opening;wherein said therapeutic agent is selected from the group consisting of an antiamyloid antibody, an anti-tau antibody, a viral gene therapy vector, a lipid nanoparticle nucleic acid delivery construct, a CRISPR-Cas9 gene editing complex, a small-molecule CNS drug, and a cell-based therapeutic.
5. A catheter-based acoustic energy delivery system for superior sagittal sinus deployment, comprising:a catheter body navigable within a lumen of the superior sagittal sinus;at least one transducer element oriented to emit acoustic energy radially outward through a wall of the superior sagittal sinus, dura mater, and cerebrospinal fluid toward ipsilateral cerebral cortex;an acoustic window integrated into a wall of the catheter body; andCHZ-00225a control system configurable to operate in at least two of the following modes: bloodbrain barrier modulation mode, thermal ablation mode, neuromodulation mode, and intravascular imaging mode.
6. The system of claim 1, wherein the ultrasound transducer element is frequency -tunable across 1 kHz to 100 MHz, and a frequency of the ultrasound transducer element is adjusted based on target tissue depth and acoustic impedance.
7. The system of claim 1, wherein the acoustic window enables at least 180-degree radial emission.
8. The system of claim 1, further comprising at least one drug delivery lumen and at least one cooling lumen, wherein said lumens operate independently from the ultrasound transducer element.
9. The system of claim 1, further comprising a fiberoptic element configured to transmit control signals, receive feedback, or deliver optical energy for adjunctive therapy or sensing.
10. The system of claim 1, further comprising an expandable scaffold proximal to the ultrasound transducer element, configured to maintain catheter position, center the ultrasound transducer element within a vessel lumen, and prevent direct vessel wall contact.
11. The system of claim 1 , further comprising a temperature sensor, wherein the control system is configured as a closed-loop control system comprising a feedback controller configured to adjust energy delivery based on inputs from the temperature sensor to maintain a thermal dose below reversible tissue injury thresholds.
12. The system of claim 1, further comprising a passive cavitation detection subsystem comprising at least one passive acoustic detector configured to detect sub-harmonic, ultraharmonic, and broadband acoustic emissions, wherein the control system adjusts output power based on cavitation spectral signatures.
13. The system of claim 1, wherein the ultrasound transducer element is capable of switching between an imaging mode and a therapeutic mode.
14. The system of claim 1, wherein the catheter body includes a steerable distal segment for navigating tortuous intracranial vasculature.
15. The system of claim 1, wherein the catheter body is configured for deployment within the straight sinus, and the at least one transducer element comprises a multi-element curved phased array conforming to a triangular cross-section of the straight sinus.CHZ-0022516. The system of claim 1, further including platinum-iridium radiopaque markers for fluoroscopic position confirmation.
17. The system of claim 3, wherein the transducer array comprises PMN-PT single crystal elements with an electromechanical coupling coefficient kt greater than 0.65.
18. The system of claim 3, wherein the closed-loop control system is configured to: increase output pressure upon absence of stable cavitation signature; reduce output pressure by at least 30% upon detection of inertial cavitation signature; and abort treatment of a sonication zone upon detection of broadband noise elevation exceeding 40 dB above baseline.
19. The method of claim 2, wherein the therapeutic agent is an anti-amyloid beta antibody selected from lecanemab, donanemab, or aducanumab, and the dural venous sinus is the straight sinus.
20. The method of claim 2, wherein the therapeutic agent is an adeno-associated viral (AAV) vector carrying a therapeutic transgene.
21. The method of claim 2, wherein the therapeutic agent is a lipid nanoparticle construct carrying mRNA, siRNA, antisense oligonucleotide, or CRISPR-Cas9 gene editing components.
22. The method of claim 2, wherein the therapeutic agent is a cell-based therapeutic construct.
23. The method of claim 2, further comprising monitoring cavitation signatures via passive cavitation detection elements integrated into the catheter, and adjusting ultrasound output parameters in real time based on said signatures.
24. The method of claim 2, wherein the dural venous sinus is the superior sagittal sinus, and acoustic energy is emitted radially outward to target medial cortical structures including the posterior cingulate cortex and precuneus.
25. The method of claim 4, wherein the neurological condition is Alzheimer's disease, and the therapeutic agent is an anti-amyloid protofibril antibody.
26. The method of claim 4, wherein the therapeutic agent is a gene therapy vector comprising AAV serotype selected from AAV1, AAV2, AAV5, AAV9, or AAVrhlO, carrying a therapeutic transgene for neuronal or glial expression.CHZ-0022527. The method of claim 4, further comprising: obtaining pre-procedure MR venography; planning sonication zones on treatment planning software; and confirming blood-brain barrier opening by gadolinium-enhanced MRI within 60 minutes of procedure completion.
28. The system of claim 5, wherein in blood-brain barrier modulation mode the system operates at a mechanical index between 0.2 and 0.6 with pulsed waveforms; in thermal ablation mode the system operates at high-intensity continuous or high-duty -cycle waveforms; in neuromodulation mode the system operates at ISPTA below 100 mW / cm2 with pulsed low-duty -cycle waveforms; and in intravascular imaging mode the system operates at frequencies between 20 MHz and 50 MHz in pulse-echo mode.
29. A therapeutic and diagnostic ultrasound system for intracranial vessel applications, comprising:an elongated catheter body configured for navigation through intracranial arteries or veins;at least one ultrasound transducer element integrated within or at a distal end of said catheter body;an acoustic window formed in a wall of the catheter body or at a tip of the catheter body, composed of a material selected from the group consisting of Pebax and other low-attenuation acoustic transmission materials; anda control system operatively connected to said at least one ultrasound transducer element;wherein said at least one ultrasound transducer element is configured to emit acoustic energy in at least one of the following directions: radially outward from the catheter body, circumferentially around the catheter body, or axially forward from the tip of the catheter body; andwherein the system operates without requiring transcranial beam steering or extracranial phased-array control.
30. The system of claim 29, wherein the ultrasound transducer element is tunable across 1 kHz to 100 MHz, and a frequency of the ultrasound transducer element is adjusted based on tissue acoustic impedance.
31. The system of claim 29, wherein the acoustic window enables at least 180-degree radial emission and includes angular emission control.CHZ-0022532. The system of claim 29, further comprising at least one drug delivery lumen and at least one cooling lumen, wherein said lumens operate independently from the ultrasound transducer element.
33. The system of claim 29, further comprising a fiberoptic element configured to transmit control signals, receive feedback, or deliver optical energy for adjunctive therapy or sensing.
34. The system of claim 29, further comprising an expandable scaffold proximal to the ultrasound transducer element, configured to maintain catheter position, center the ultrasound transducer element within a vessel lumen, and prevent direct vessel wall contact.
35. The system of claim 29, further comprising a temperature sensor and a proximity sensor, wherein the control system is configured as a closed-loop control system comprising a feedback controller configured to adjust energy delivery based on inputs from the temperature sensor and the proximity sensor.
36. The system of claim 29, wherein the catheter body includes a steerable distal segment for navigating tortuous intracranial vasculature.
37. The system of claim 29, wherein the system further includes positional sensing for realtime emitter localization.
38. The system of claim 29, wherein the ultrasound transducer element is capable of switching between an imaging mode and a therapeutic mode.
39. The system of claim 29, wherein the control system includes a programmable console configured to adjust emission frequency, pulse duration, and treatment sequence in real time.
40. The system of claim 29, further configured to monitor intravascular structures, comprising: a signal processing unit for detecting and characterizing the presence of indwelling medical devices, thrombi, calcifications, or foreign bodies within the vessel lumen based on acoustic backscatter or Doppler signatures; wherein said monitoring capability is operable in real-time and co-registered with energy delivery pathways.
41. A method for delivering therapeutic or diagnostic acoustic energy within an intracranial vessel, comprising:positioning a catheter within an intracranial artery or vein; generating acoustic energy at a frequency between 1 kHz and 100 MHz;CHZ-00225emitting said acoustic energy through an acoustic window located in a wall of the catheter or at a tip of the catheter in a direction selected from the group consisting of radial, circumferential, and axial emission;and modulating said energy delivery based on proximity to vessel walls or surrounding tissue;wherein said method does not require transcranial beam steering or extracranial phased-array control.
42. The method of claim 41, further comprising measuring tissue temperature, adjusting emission parameters based on the temperature, and delivering a therapeutic compound concurrently.
43. The method of claim 41, wherein positioning the catheter includes advancement through a guide catheter, placement under fluoroscopic or ultrasound imaging, and deployment of a scaffold to anchor position.
44. The method of claim 41, wherein modulating energy delivery includes real-time distance monitoring, adaptive energy output based on proximity and tissue compliance, and frequency adjustment based on feedback.
45. The method of claim 41, further comprising measuring blood flow velocity or pulsatility, modifying treatment parameters based on flow dynamics, and logging treatment data via fiberoptic telemetry.
46. The method of claim 41, wherein emission is pulsed with a variable duty cycle, and active cooling is applied between pulses.
47. The method of claim 41, further comprising administering a sensitizing agent or microbubble contrast during acoustic emission.
48. An intravascular focused ultrasound catheter system for ablation of hepatic, pancreatic, renal, adrenal, and retroperitoneal tumors, the system comprising:a flexible elongated catheter body having a proximal connector end and a distal therapeutic end, wherein the catheter is configured for percutaneous deployment within the inferior vena cava or a hepatic vein via femoral venous access;a dual-frequency phased array transducer assembly disposed at the distal therapeutic end, comprising:CHZ-00225a first set of piezoelectric elements configured to transmit and receive ultrasound at a first imaging frequency in the range of 5-15 MHz for real-time B- mode visualization of target tissue, anda second set of piezoelectric elements configured to transmit focused ultrasound at a second therapeutic frequency in the range of 1-3 MHz for thermal ablation of said target tissue;an electronic beamforming system operatively coupled to the transducer assembly, configured to electronically steer a therapeutic focal zone to a selectable depth of 10-100 mm from a longitudinal axis of the catheter body without physical repositioning of the catheter;a processor executing a closed-loop thermal dosimetry algorithm configured to estimate cumulative thermal dose at said therapeutic focal zone from acoustic backscatter data and to terminate therapeutic ultrasound delivery upon reaching a predetermined thermal dose threshold.
49. The catheter system of claim 48, wherein the first and second sets of piezoelectric elements are interleaved in a linear array configuration along the longitudinal axis of the catheter body, separated by an acoustic isolation layer, and wherein both sets share a common acoustic lens providing a default geometric focus at 25-35 mm from the longitudinal axis of the catheter body.
50. The catheter system of claim 48, wherein the piezoelectric elements comprise PMN-PT single crystal material having a piezoelectric constant dii of at least 1200 pC / N, enabling high-efficiency acoustic power generation from a catheter outer diameter of 4.0-5.0 mm.
51. The catheter system of claim 48, further comprising one or more passive cavitation detection elements disposed on the catheter body within 10 mm of the transducer assembly, configured to detect sub-harmonic and broadband acoustic emissions during therapeutic operation, and a hardware interlock configured to reduce therapeutic power by at least 30% within 2 ms upon detection of inertial cavitation signatures.
52. The catheter system of claim 48, further comprising an active cooling lumen configured to deliver a cooling fluid at a flow rate of 20-50 mL / min through the catheter distal segment, and one or more exit ports disposed proximal to the transducer assembly, wherein said cooling fluid reduces IVC wall temperature to maintain tissue temperature at the vessel wall below 43 °C during therapeutic operation.CHZ-0022553. The catheter system of claim 48, further comprising a motion compensation system comprising: a real-time speckle tracking algorithm operating on sequential B-mode image frames at a frame rate of at least 20 Hz to estimate 2D displacement of the target tissue; and a beamforming correction system configured to apply phase delays to the second set of piezoelectric elements to dynamically track the moving focal target within a compensation range of ±5 mm.
54. The catheter system of claim 53, wherein therapeutic ultrasound delivery is gated to respiratory exhalation phases, as determined from acoustic signal variance in the B-mode imaging data, to reduce motion artifacts during ablation of hepatic targets subject to respiratory excursion.
55. The catheter system of claim 48, wherein tissue temperature is estimated by analysis of frequency -dependent backscatter spectral shift in echoes received by the first set of piezoelectric elements, exploiting the temperature dependence of tissue speed of sound, without requiring external thermometry apparatus.
56. A method for thermally ablating a tumor using an endovascular approach, the method comprising:percutaneously inserting a dual-mode focused ultrasound catheter into a femoral vein and advancing the catheter to a position within the inferior vena cava or a hepatic vein anatomically adjacent to the tumor;activating a high-frequency imaging mode of the catheter at 5-15 MHz to acquire real-time B-mode ultrasound images of the tumor and surrounding hepatic or pancreatic tissue; delineating the boundaries of the tumor on the acquired B-mode images and programming a plurality of focal ablation zones within a volume of the tumor;activating a therapeutic focused ultrasound mode of the catheter at 1-3 MHz and sequentially sonicating each programmed focal zone;monitoring cumulative thermal dose at each focal zone from acoustic backscatter data; andterminating sonication at each zone upon reaching a predetermined thermal dose threshold, wherein said high-frequency imaging mode and said therapeutic focused ultrasound mode are performed without removing or repositioning the catheter.CHZ-0022557. The method of claim 56, further comprising administering ultrasound contrast microbubbles intravenously prior to the therapeutic mode to enhance acoustic energy deposition and reduce the acoustic power required for ablation, and monitoring passive cavitation emissions during sonication to detect and prevent inertial cavitation.
58. The method of claim 56, wherein the step of sonicating includes applying electronic focal steering to ablate a tumor volume up to 5 cm in maximum diameter by overlapping individual focal zones of 3-8 mm diameter without mechanical repositioning of the catheter.
59. A dual-frequency intravascular ultrasound transducer assembly for simultaneous diagnostic imaging and therapeutic ablation, comprising:a first linear array of at least 8 piezoelectric elements resonant at a first therapeutic frequency of 1-3 MHz, arranged with an element pitch of 0.4— 0.7 mm in the azimuthal direction;a second linear array of at least 16 piezoelectric elements resonant at a second imaging frequency of 5-15 MHz, arranged with an element pitch of 0.2-0.3 mm in the azimuthal direction;wherein the first and second arrays are co-located on a common substrate within a total axial footprint of 40 mm or less and an outer diameter of 5 mm or less, making the assembly suitable for deployment within a human blood vessel;an acoustic impedance matching layer covering both arrays; anda backing material providing at least -35 dB attenuation of backward-propagating acoustic energy.
60. The transducer assembly of claim 59, wherein the first and second arrays are interleaved in a row-column configuration, with the piezoelectric elements of the second linear array disposed between adjacent piezoelectric elements of the first linear array in the azimuthal direction, enabling spatially coincident imaging and therapeutic beam patterns.
61. The transducer assembly of claim 59, wherein the piezoelectric elements of both arrays are fabricated from PMN-PT single crystal and are individually addressable through independent coaxial signal conductors, enabling independent phase and amplitude control for real-time electronic focus steering of both an imaging beam and a therapeutic beams.
62. The transducer assembly of claim 59, further comprising a curved acoustic lens providing a fixed geometric focal length of 20-40 mm in an elevation dimension, wherein electronicCHZ-00225steering of both the imaging beam and the therapeutic beam is performed in the azimuthal direction over a range of ±45° from a longitudinal axis of the transducer assembly.
63. The system of claims 1, 5, or 29, wherein the at least one ultrasound transducer element comprises a multi-element phased array in which each element is individually addressable to enable electronic beam steering and focal depth variation from 5 mm to 60 mm from a longitudinal axis of the catheter body without mechanical repositioning of the catheter body.
64. The system of claim 5, wherein the at least one transducer element comprises a phased array configured to electronically steer an acoustic focus in an azimuthal dimension over a range of ±25° and to a selectable focal depth of 5 mm to 50 mm from the sinus wall toward ipsilateral cerebral cortex.
65. The system of claim 3, wherein the transducer array is configured to electronically steer an acoustic focus in the azimuthal dimension over a range of at least ±25° from the catheter longitudinal axis, enabling bilateral targeting of hippocampal structures from a single catheter position within the straight sinus.
66. The method of claim 4, wherein the neurological condition is selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington’s disease, multiple sclerosis, spinal muscular atrophy, lysosomal storage disorders with CNS involvement, glioblastoma, epilepsy, traumatic brain injury, and CNS metastatic disease.
67. The method of claim 26, wherein the therapeutic transgene is selected from the group consisting of: GBA for Parkinson’s disease or Gaucher’s disease with CNS involvement; SMN1 for spinal muscular atrophy; an HTT-silencing construct for Huntington’s disease; ASPA for Canavan disease; CLN2, CLN3, or CLN6 for neuronal ceroid lipofuscinoses (Batten disease); LRRK2 or SNCA for Parkinson’s disease; S GDI -targeting constructs for amyotrophic lateral sclerosis; progranulin (GRN) for frontotemporal dementia; and NAGLU for Sanfilippo syndrome type B.
68. The method of claim 4, wherein the cell-based therapeutic is selected from the group consisting of: chimeric antigen receptor T cells (CAR-T) targeting a CNS tumor antigen; neural stem cell-derived progenitors for neurodegenerative disease; regulatory T cells for neuroinflammatory conditions; and induced pluripotent stem cell-derived dopaminergic neurons for Parkinson’s disease.CHZ-0022569. The system of claim 5, wherein the control system is further configurable to operate in a sonodynamic therapy mode in which acoustic energy is delivered in combination with a systemically administered sonosensitizer agent.
70. The system of claim 5, wherein the control system is further configurable to operate in a sonothrombolysis mode in which moderate-intensity pulsed focused ultrasound is delivered.
71. The method of claim 2, wherein the therapeutic agent is a monoclonal antibody targeting a CNS pathological protein aggregate selected from the group consisting of amyloid-beta, tau, alpha-synuclein, TDP-43, FUS, and huntingtin protein.
72. The method of claim 2 or claim 4, wherein the therapeutic agent is a recombinant enzyme selected for replacement therapy in a lysosomal storage disorder with CNS involvement, including but not limited to glucocerebrosidase for Gaucher’s disease, iduronate-2-sulfatase for Hunter syndrome, alpha-L-iduronidase for Hurler syndrome, and N-acetylglucosaminidase for Sanfilippo syndrome type B.
73. The system of claim 1, wherein the acoustic window includes angular emission control configured to selectively direct acoustic energy output to a defined angular sector of a radial emission field by segmented activation of transducer sub-elements, mechanical rotation of a directional emitter, or incorporation of an asymmetric acoustic reflector or absorber within the catheter body.
74. A coordinated intracranial focused ultrasound system comprising:a first catheter configured for deployment within the superior sagittal sinus and configured for radial or circumferential acoustic energy delivery to medial cortical structures;a second catheter configured for deployment within the straight sinus and comprising a multi-element curved phased array configured for focused acoustic energy delivery to hippocampal-entorhinal circuit structures at focal depths of 5 mm to 60 mm; anda coordinating control system configured to operate said first and second catheters simultaneously or sequentially during a single interventional procedure.
75. A method for delivering focused acoustic energy to intracranial tissue using phased-array-guided intravascular ultrasound, comprising:positioning a catheter comprising a multi-element phased array within a dural venous sinus or intracranial vein; electronically steering an acoustic focus of the multi-element phased array to a target tissue depth of 5 mm to 60 mm from the catheter axis;CHZ-00225delivering pulsed or continuous acoustic energy to the target tissue; and modulating energy delivery parameters in real time based on feedback from at least one of a passive cavitation detection subsystem, a temperature sensor, or a proximity sensor.
76. The system of claim 1, wherein the catheter body is constructed from non-ferromagnetic materials and signal transmission is provided via fiberoptic pathways, such that the system is compatible with magnetic resonance imaging environments.
77. The system of claims 1, 5, or 29, wherein the at least one ultrasound transducer element comprises a multi-element phased array in which each element is individually addressable to enable electronic beam steering and focal depth variation from 5 to 60 mm from the catheter axis without mechanical repositioning of the catheter body, with an azimuthal steering range of at least ±25°.
78. The system of claim 1, wherein the catheter body comprises non-ferromagnetic materials and fiberoptic signal pathways configured for magnetic resonance imaging compatibility.
79. The system of claim 1 or 5, further comprising an electronic beamforming system operatively coupled to the at least one ultrasound transducer element, configured to electronically steer a therapeutic focal zone to a selectable depth from a longitudinal axis of the catheter body without physical repositioning of the catheter, and a processor executing a closed-loop thermal dosimetry algorithm configured to estimate cumulative thermal dose at the focal zone from acoustic backscatter data and to terminate energy delivery upon reaching a predetermined thermal dose threshold.
80. The system of claim 5, wherein the at least one transducer element is configured to deliver acoustic energy over a radial emission coverage range of up to 5 cm from the catheter body.
81. The system of claim 73, wherein the angular emission control is configured to direct acoustic energy as a directed arc of less than 360 degrees.
82. The method of claim 4, wherein the therapeutic agent is a gene therapy vector carrying a therapeutic transgene, wherein the therapeutic transgene is selected from: a transgene encoding an enzyme whose deficiency causes a CNS -manifesting enzyme deficiency disorder; or an inhibitory nucleic acid construct targeting a gene product associated with pathological protein aggregation in a neurodegenerative disease.
